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ABSTRACT  
 An in vitro comparison of the osteogenic potential of equine stem cell 
populations and subpopulations from multiple tissue sources was made to identify the 
ideal equine donor tissue as a source of MSCs to promote bone healing. Equine muscle 
tissue– and periosteal tissue–derived cells where characterized as mesenchymal stem 
cells (MSCs) and their proliferation capacity and osteogenic potential was assessed in 
comparison with bone marrow– and adipose tissue–derived MSCs. Cells were isolated 
from skeletal muscle, periosteal, and adipose tissues, and sternal bone marrow aspirates. 
Morphology, adherence to plastic, trilineage differentiation, and detection of stem cell 
surface markers CD44 and CD90 were used to characterize cells as MSCs. Osteogenic 
potential of MSCs was measured by osteocalcin gene expression.  Mesenchymal stromal 
cell cultures were counted at 24, 48, 72, and 96 hours to determine tissue-specific MSC 
proliferative capacity. Muscle MSCs (MMSCs), periosteum MSCs (PMSCs), and 
adipose MSCs (AMSCs) proliferated significantly faster than did bone marrow MSCs 
(BMSCs) at 72 and 96 hours.  
 Non-equilibrium gravitational field-flow fractionation (GrFFF) was validated as 
a method for sorting MSCs from four donor sources (muscle, periosteum, bone marrow, 
and adipose tissue) into subpopulations. Aliquots of MSCs from each tissue source were 
consistently separated into 6 fractions by continuous flow (GrFFF proprietary system) 
and these fractions remained viable for use in further assays.  Absorbencies (OD) were 
compared, and trilineage assays performed.  Statistical analysis of the fraction 
absorbencies (OD) revealed a P-value of <0.05 when fraction 2 and 3 were compared to 
fractions 1, 4, 5, and 6.  
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  GrFFF was used to sort MMSCs and BMSCs into subpopulations and perform 
assays allowing comparison of their osteogenic capabilities. Aliquots of MMSCs and 
BMSCs were sorted into 5 fractions using non-equilibrium GrFFF.  Pooled fractions 
were cultured and expanded for assays including: flow cytometry, histochemistry, bone 
nodule assays, and real time PCR to identify upregulation of osteocalcin, RUNX2, and 
osterix. There was significant upregulation of  osteocalcin, RUNX2, and osterix for the 
BMSC fraction 4 with P<0.00001 indicating high osteogenic potential.  Flow cytometry 
revealed different cell size and granularity for BMSC fraction 4 and MMSC fraction 2 
when compared with unsorted controls and other fractions.  Histochemistry and bone 
nodule assays revealed positive staining nodules but no significant differences between 
tissues or fractions. 
 It was concluded that 1) equine muscle and periosteum are sources of MSCs that 
have osteogenic potential comparable to that of equine adipose- and bone marrow–
derived MSCs, 2) non-equilibrium GrFFF is a valid method for sorting equine MMSCs, 
PMSCs, BMSCs, AMSCs into subpopulations that remain viable and 3)subpopulations 
of MSCs exist and have different osteogenic capacities within equine muscle and bone 
marrow derived sources. These findings are important contributions to equine stem cell 
therapy and bone healing in veterinary medicine. 
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1 GENERAL INTRODUCTION  
1.1 The problem 
 Rigid internal fixation and external coaptation are adequate techniques to allow 
natural healing of most fractures in most species.(1-4)  When faced with a bone defect 
that exceeds the natural healing capabilities of the animal, such as a delayed or a non-
union, many strategies have been implemented to promote healing.(5)  Bone grafts, and 
bone marrow injections are primarily performed in veterinary species while in vitro 
expansion of autologous bone marrow derived mesenchymal stem cells (MSCs) and 
later injection has been successful in recent human cases of non-union.(6)  Many new 
approaches are based on bone producing MSCs, and cell based therapies, providing 
surgeons with more treatment options in the near future.(7) 
 When MSCs are injected they tend to migrate through the body by means of 
chemotaxis or ‘homing’ to tissues that are need of repair.  When intended to stay at the 
site of injection, scaffolds are used to keep MSCs in place and give them a structure in 
which to congregate.(8) The ideal scaffold is biocompatible, absorbable, 
osteoconductive, osteoinductive, highly porous, and reproducible.(9) Some of the 
scaffolds currently under investigation are hydroxapatite,(10) tricalcium phosphate,(11) 
demineralized bone,(12-14) coral,(15) collagen,(16) and hydrogel.(9) Scaffolds can also 
serve as vehicles to deliver various factors to enhance bone healing.(10) Bone 
metabolism and homeostasis are regulated by many hormones and growth factors such 
as parathyroid hormone (PTH), insulin-like growth factors (IGFs), platelet-derived 
growth factor (PDGF), fibroblast growth factors (FGFs), vascular-endothelial growth 
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factors (VEGFs), transforming growth factors (TGF), and bone morphogenetic proteins 
(BMPs).(17) Knowledge of the physiological roles of these components of bone 
formation makes them useful targets for optimization of osteogenesis. However, the gold 
standard MSC scaffold/growth factor combination in osteogenesis has not been 
determined but is likely to be major factor in successful promotion of bone healing.(9)  
 The challenge of timely bone healing is of particular significance in the equine 
industry.  Catastrophic breakdown is a major source of wastage in racehorses, with as 
many as 67%-89% of deaths attributed to exercise-related injury.(18-20) Fractures 
account for 71% in UK, 88% in California, and 92.7% in Mid-west USA, of fatal 
musculoskeletal injuries in racing Thoroughbreds.(18, 19, 21, 22) The initial surgical 
stabilization of equine fractures with metal plates and screws is costly at $2,000-
$10,000(23) and cost increases with the onset of complications the accompanying 
prolonged hospital stay.(24) Due to their size and temperament, horses must remain 
weight bearing on all four limbs during the healing process.(25) If not comfortable on all 
four limbs horses are prone to the development of contralateral limb laminitis due the 
uneven weight sharing between limbs while recovering.(26)  Many horses tolerate 
slings, which lessen the load on both the fractured and contralateral limbs, but patient 
selection is key and therefore they are not always an option.(27)  This leaves the surgical 
repair susceptible to breakdown and failure because the constant loading of implants 
often causes fatigue and ultimately failure of the metal screws and plates.(28, 29) The 
constant loading combined with the fact that equine fractures heal much more slowly 
than those of other veterinary species,(30) lead to life threatening complications and a 
poor prognosis for most equine fracture patients.  In addition, many adult equine 
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fractures are high energy fractures with much soft tissue trauma.(31)  Without viable 
soft tissues covering a fracture repair, bone repair has been shown to be delayed.(32)  
Other postoperative complications include those attributable to inadequate tissue 
coverage and blood supply, as well as bacterial contamination:  incisional infection, 
implant infection, and non-union of fracture(11); those due to uneven weight sharing and 
cyclic loading: contralateral limb laminitis,  and implant failure or loosening/ breakage; 
and those due to stress and antimicrobial therapy; colic, and diarrhea.(33, 34)  
 
 If equine fracture healing rates could be increased, the prolonged hospital stays 
could be shortened and complications such as non-union of fractures and contralateral 
limb laminitis would decrease, thus increasing survival rates and  making the initial fee 
of fixation a more worthwhile investment to owners.  To this end, veterinary researchers 
are active in areas of research for infection prevention, improving implant design, and 
methods of increasing osteogenesis itself. (11, 27, 35, 36)  Conventionally, bone healing 
is best enhanced with the current gold standard, cancellous bone grafts.(35)  However, 
the successful utilization of a cancellous bone graft is limited by supply, the additional 
surgical site required, increased time required for harvesting and placement, cost, and 
potential donor site morbidity associated with its harvest.(5) Therefore, it would be 
beneficial to our veterinary patients to identify other potential sources of graft substitutes 
such as mesenchymal stem cells (MSCs) that could enhance osteogenesis.   
 
1.2  MSC research to date – sources and applications 
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 Stem cell research aimed towards tissue regeneration is an expanding field in 
both human and veterinary medicine.(37) MSCs are defined by their capacity to 
differentiate into a variety of other cell types including fat, cartilage, bone, muscle, and 
nerve cells.(38) There is evidence in the lab animal,(39-42) and human literature to 
support the notion that MSCs may be used to enhance healing and repair of 
musculoskeletal defects including those affecting bone.(6, 43, 44)  Human bone marrow 
derived MSCs have been shown to promote bone healing in long bone and skull defects 
in laboratory animal models.(45, 46)  In large animals, sheep bone marrow derived 
MSCs implanted in porous hydroxyapatite ceramic carriers also showed greater bone 
deposition in a shorter time period, in a tibial ostectomy model, when compared to the 
carrier alone.(47) In horses, equine MSCs have been used in vivo to improve cartilage 
healing,(48) and tendon healing,(49, 50) but bone healing still requires an in vivo trial to 
assess efficacy.  The osteogenic potential of bone marrow derived MSCs has been the 
most thoroughly researched donor source.(51) Details about bone marrow derived MSCs 
and osteogenesis, such as proper culture conditions,(52, 53) scaffold effects,(54) 
differentiation potential, (51) and growth characteristics,(55) have been elucidated. New 
insight is necessary into tissue sources that are easily harvested and yield high numbers 
of MSCs.  Therefore, new research into the osteogenic potential of other potential graft 
substitutes, such as other sources of MSCs, are a valid and necessary next step in the 
search for methods to increase the rate of equine bone healing. 
Research in lab animals and humans has revealed many potential donor sources 
of MSCs; bone marrow and adipose tissue,(56) derivations of umbilical cord,(57-59) 
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periosteum,(60) synovial membrane,(61) muscle,(62) dental pulp,(63) and cardiac 
muscle.(64)  In horses the most commonly used sources are bone marrow and adipose 
tissue,(65) but less conventional sources have been explored including; umbilical cord 
blood and tissue,(66-68) Wharton’s Jelly,(69) amnion,(70) amniotic fluid,(71) tendon 
and muscle,(72) and blood.(73)  Thus, a major focus in the following studies was to 
assess the osteogenic capacities and to characterize periosteum and muscle as novel 
donor sources of MSCs in horses.   
 
1.3 Novel sources of MSCs 
In vitro studies identified periosteum,(74) and muscle tissues (75) as potential sources of 
equine osteogenic cells for use in cell based therapy.  Results have shown that MSCs can 
be isolated and expanded from periosteum and muscle tissues.   The MSCs from 
periosteum and skeletal muscle also show osteogenic differentiation when cultured in 
conventional osteogenic medium. Because properties of the donor tissues should include 
ease of harvest, minimal morbidity, optimum proliferation capacity and osteoblastic 
activity, both periosteum and skeletal muscle show promise for use in cell-based therapy 
similar to that of bone marrow and adipose tissue which have been investigated more 
thoroughly.(55) Many groups have interest in the comparison of tissue sources for MSC 
harvest and their subsequent osteogenic capacity, but none have identified a tissue 
source of MSCs that are clear leaders in osteogenesis.(51, 76) Identification of the 
optimal source of MSCs with the best osteogenic potential may prove critical in moving 
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the basic science research toward successful clinical cell based therapy to promote bone 
healing.   
1.4 Stem cells  
 It is generally accepted that stem cells can be best defined by two requirements: 
they must sustain their own population, and be capable of either toti-, pluri-, or 
multipotency.(9)  Totipotency is the ability of a single cell to differentiate into all of the 
cells in an organism.  Pluripotency is the ability of a cell to differentiate into cells of any 
of the three germ layers; endoderm (stomach lining, gastrointestinal tract, and lungs), 
ectoderm (skin and nerves), and mesoderm (muscle, bone, blood).  Multipotency is the 
term applied to cells that have the ability to differentiate into multiple but limited 
different cell types (cartlage, fat, and bone). That being said, the terminology 
surrounding stem cell therapy can be misleading as there is a lack of standard terms used 
throughout publications.(9) This makes comparing studies a challenge.  When strictly 
defined, multipotent cells that are derived from adult tissues are best described as 
mesenchymal stromal cells, not mesenchymal stem cells.(9) This distinction is made to 
avoid use of the word ‘stem’ when the cell is multipotent, not pluripotent, and cannot 
self renew indefinitely.(77) However, in an effort to be consistent with the majority of 
the published literature that refers to multipotent cells that are derived from adult tissues 
as mesenchymal stem cells, the studies in this thesis follow suit.     
 MSCs also display a bimodal effect on the immune system by secretion of 
bioactive factors that are trophic and immunomodulatory.(78)  Trophic activities of 
MSCs help to stimulate angiogenesis, thus reducing apoptosis, recruit host progenitor 
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cells, and minimize fibrosis.(79) The immunomodulatory effects prevent lymphocyte 
awareness of the wounded tissue by interacting with its lymphocyte B cells, T cells, 
natural killer cells, dendritic cells, macrophages/monocytes, and neutrophils, thus 
preventing autoimmunity.(78) This down regulation of the immune response allows for 
the application of allogeneic MSCs without rejection in a variety of clinical situations. 
(80, 81) This broad range of trophic and immunomodulatory capabilities make MSCs 
highly desirable for uses in medical applications.  
1.4.1 Embryonic stem cells vs. mesenchymal stem cells 
 The greatest potential for differentiation exists in the youngest stages of 
embryologic development of the cell mass.(37) Embryonic stem cells (ESCs) are 
totipotent through the 8 cell stage of the morula;(82) therefore, at that time each cell has 
the ability to become any cell of the fetus or the fetal membranes.  At the subsequent 
blastocyst stage, cells of the inner cell mass are pluripotent, having the potential to 
differentiate into any cell in the three germ layers.(83) After birth, stem cells are 
classified as adult instead of embryonic, and as multipotent instead of pluripotent, 
having a limited potential to differentiate into multiple tissue lineages including: 
chondrogenic, adipogenic, and osteogenic.(83)  
 
 While related, there are several other differences between ESCs and MSCs.  In 
vitro culture techniques are different for ESCs and MSCs.  ESCs are non-adherent on 
plastic culture dishes and therefore must be grown on a layer of primary feeder cells.(84) 
MSCs are adherent on plastic culture dishes and require no feeder cell layer.(85)  ESCs 
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have the ability to be cultured for extended periods of time while MSCs have a limited 
lifespan.(85) This lifespan varies with tissue source of MSCs.(38) MSC and ESC based 
therapies are promising to be some of the most valuable of the new technologies 
available for bone healing.(86) 
 
1.4.2 Induced pluripotent cells  
 Induced pluripotent stem (iPS) cells are adult mesenchymal stem cells that have 
been reprogrammed to be pluripotent using viral vectors that induce the expression of 
oncogenes in the candidate cell.(87)  iPS cells are functionally similar to ECSs in many 
ways.  iPS cells have been found to be identical to ESCs in morphology, proliferation, 
gene expression, in vitro differentiation and teratoma formation.(87) Both have the 
potential to replicate indefinitely without differentiation and are capable of becoming 
any tissue in the body, but iPS cells are created from post-natal cells and circumvent the 
controversial dilemma faced by ESCs as they are harvested from adults not 
embryos.(88) This technology has created iPS cells from many species; murine,(89, 90) 
porcine,(91) ovine,(92) equine,(93-95) human (96) and many tissue sources; stomach, 
liver, skin,(97) prostate,(98) dental tissue,(99) urinary tract cells.(100) The potential for 
use of these cell lines is powerful as they present a way to create patient- and disease-
specific stem cells from an adult source.(87) Several studies are examining the safety of 
iPS cells,(101) and others have found their immunogenicity to be nonexistent.(88, 102) 
As a result, they are presently a very important area of research.(88)  
 
1.4.3 Osteoblastic stem cells 
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 The osteoblastic stem cell lineage is of great interest to researchers who seek to 
hasten bone healing for it is the cell lineage responsible for the production of bone.(84, 
103) Understanding the mechanisms of bone production by these cells is crucial.  The 
stages of differentiation begin with the MSC which first matures to an osteoprogenitor 
cell that is committed to the osteogenic lineage, and is still self renewing.  Next, 
osteoprogenitors become  preosteoblasts. Preosteoblasts only retain a limited capability 
to proliferate and start to stain positive for alkaline phosphatase enzymatic activity, 
indicating that this is a reliable early marker of the osteoblastic lineage.(104)  
Developmentally, preosteoblasts mature into osteoblasts which can be distinguished by 
their cuboidal shape, lack of ability to divide, and their expression of bone matrix 
proteins such as bone sialoprotein (BSP), runt-related transcription factor 2 (Runx2), 
osterix(Osx), osteocalcin (OCN), and alkaline phosphatase (ALP).(105) Runx2 is known 
to be expressed earlier in differentiation of osteoblasts, while Osx and OCN are known 
to be expressed later in differentiation.(52, 104, 106) Osteoblasts are normally in a 
quiescent state, and when they incorporate into the osteoid matrix they are referred to as 
osteocytes.(104)  Osteocytes are the most mature cells of the osteoblastic lineage.  In 
comparison to osteoblasts, osteocytes are smaller, have lower metabolic activity 
resulting in fewer organelles, and have a decreased alkaline phosphatase activity.(103)  
Figure 1.1 
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Figure 1.1 Expression of the addressed bone matrix proteins of the osteogenic cell 
lineage. Bone sialoprotein = BSP, Runt-related transcription factor 2 = Runx2, Osterix = 
Osx, Osteocalcin = OCN, and Alkaline phosphatase = ALP. 
 
 In vitro cultures of the cells from the osteoblastic lineage progress through a 
characteristic series of developmental stages.(107) The first recognizable stages are 
proliferation, then matrix development, and finally mineralization into nodules.(74)  
Different hormones and growth factors influence the in vitro development of 
osteoblastic cell lines at various stages.(104, 108) Osteoprogenitors may be influenced 
both in division and their ability to form nodules.(104)  For example, the addition of 
glucocorticoids, most commonly dexamethasone, has been shown to increase the size 
and number of bone nodules,(109) as well as alkaline phosphatase enzymatic 
activity.(52) Ascorbic acid and β-glycerophosphate have been shown to enhance the 
mineralization of bone nodules.(107)  The ability to consistently and repeatedly 
manipulate cells in the osteoblastic lineage in vitro is a critical prequisite to using these 
cells in vivo.(44) 
 
1.5 Techniques to confirm the identity of cell lineages 
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 Many molecular biological techniques have been implemented to confirm the 
cell lineages isolated and expanded in cell cultures.  Expression of genes, detection of 
proteins of interest, and detection of cell surface markers are a few of the strategies 
being used.   
 
1.5.1 Polymerase chain reaction  
 Polymerase chain reaction (PCR) is a method routinely employed in cell based 
research to identify the expression of specific genes.(110) The popularity of PCR is in 
part due to the fact that other techniques for detection of gene expression such as 
Northern and Southern Blots, require larger starting amounts of RNA and DNA 
respectively which can be tedious to generate in cell cultures.(111) PCR provides a way 
to exponentially replicate a small sample of a relatively short piece of DNA thus 
producing enough DNA that it can be tested and quantified.(112) PCR consists of 20-40 
cycles through three different temperature steps known as thermal cycling.  The first 
step takes place at 90-98
o
C for 20-30sec and causes the denaturation of the DNA, and 
the destruction of hydrogen bonds between complimentary bases resulting in single 
stranded DNA (ssDNA).  The next step occurs at 50-65
o
C for 20-40sec and involves the 
annealing of the primers to their complementary DNA sequences. Finally the elongation 
step reaches 72
o
C for 40-50secs, and nucleotides assemble along the ssDNA templates.  
Traditionally, agarose gel electrophoresis has been employed to visualize the PCR 
products and these are compared to a DNA ladder of known molecular weights.  As this 
method for assessing amplicons is primarily qualitative in nature, real time quantitative 
PCR (qPCR) has been developed and is currently more often employed.(113) 
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 1.5.2  Real time quantitative PCR  
qPCR measures mRNA expression of the gene of interest compared to baseline 
expression of a reference (housekeeping) gene that is expressed at the same level in all 
cells. Normalizing expression levels of the gene of interest to this reference gene ensures 
that changes in gene expression are due to true biological differences, rather than 
differences in starting amounts of sample.  Glyceraldehyde-3-phosphate dehydrogenase 
mRNA (GAPDH) is the housekeeping gene used in the experiments in this thesis 
because its expression levels were found by our preliminary work to have the least 
fluctuation when compared to other potential housekeeping genes such as actin mRNA, 
and major histocompatibility complex 1.  This finding of uniform GAPDH expression is 
consistent with previous qPCR studies in equine bone(114) and equine 
endometrium.(115) 
 Real time qPCR measures DNA, cDNA, or RNA expression of the gene of 
interest during the logarithmic phase of amplification instead of after the reactions are 
complete.(116-118) As the copies of DNA (cDNA) are amplified, a flourochrome, 
SYBR green, intercalates between the double-stranded DNA and fluoresces.(119, 120) 
This non-specific binding allows the DNA product to fluoresce to some degree, 
regardless of whether it is a contaminate gene or a gene of interest.(121, 122) For this 
reason, the melting point of each end product is measured and should be consistent with 
the known gene of interest’s melting point if it is indeed pure.(119) The melting point is 
the temperature at which 50% of the DNA is denatured and it can be used to indentify 
PCR products. Impurities in a sample will cause it to have a separate melting point peak 
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from the other samples run in parallel.(123)  The increasing intensity of fluorescence can 
be graphed and measured by a computer program as it takes place allowing for 
quantitative analysis of the reaction.  A preset consistent florescence threshold is crossed 
as the DNA is amplified, and the number of cycles completed before reaching that 
threshold is called the CT value. CT levels are inversely proportional to the amount of 
target nucleic acid in the sample (ie the lower the CT level the greater the amount of 
target nucleic acid in the sample).(117)   
 
 There are several methods to quantitate the mRNA levels that are obtained 
during qPCR.  They are divided into absolute and relative quantification.  Absolute 
quantification has been used to determine the absolute transcript copy number.(124-126) 
A standard curve is used to display the fold change in expression of the target and 
reference genes allowing for comparison.(127) While this gives quality information, it 
requires that you create a dilution curve for each reference and gene of interest on each 
plate.  As this is tedious, and prone to dilution error that would render the data unusable, 
the standard curve method was not used in the research described in this thesis.  The two 
most widely used relative quantification methods are the Pfaffl method and the 
comparative CT method (2
-ΔΔC
T).  The Pfaffl method is a mathematical model that 
calculates the efficiency ratio of the reference gene to the gene of interest and therefore 
does not need a standard curve to do comparisons.(128) The comparative CT method 
avoids the use of a standard curve as well as the calculation of gene efficiencies.  In so 
doing it makes two assumptions that must be supported by the data.  The first 
assumption is that the efficiency of the qPCR is close to 1 and the second is that the 
 14 
 
efficiency of the reference gene and gene of interest are similar.(129) The efficiency was 
determined using bone derived MSCs as a positive control and a standard curve in 
preliminary work done before this thesis.  As the efficiencies for qPCR assays used in 
the thesis research were ≥.98, the studies hereafter used the comparative CT method to 
compare the gene expression between cell samples treated with osteogenic media and 
control samples of cells in standard media.  This allowed the data to be presented as ‘the 
expression of the gene of interest relative to the internal control or reference gene 
(GAPDH) in the treated sample (osteogenic media) compared with the untreated control 
(standard media).’(130) 
 
 1.5.3  Fluorescence-activated cell sorting, flow cytometry and 
immunofluorescence 
  The identification and enumeration of cells is a significant challenge in cell 
based research.  Three biomedical techniques that rely on cell surface antigens and their 
interactions with antibodies are fluorescence-activated cell sorting (FACS), flow 
cytometry and immunofluorescence.(110) All three methods start by exposing a cell 
culture to fluorophore tagged antibodies for specific cell surface antigens.  FACS and 
flow cytometry then suspend cells in a stream of fluid as a laser source is transmitted 
through the stream.(131)  The specific light scattering and fluorescent characteristics of 
each cell allow them to be counted for flow cytometry, or to be counted and sorted one 
cell at a time, for FACS.  Flow cytometry provides a quantitative reading of 
fluorescence from individual cells, and FACS provides this as well as a physical 
separation of cells of particular interest. To this end, the cells are tagged by antibodies 
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and fluorescent labels in preparation for the techniques thus changing their cell surface 
characteristics and impeding post-FACS/flow cytometric assays.(132)  Despite this 
drawback, FACS is currently the standard for sorting populations and subpopulations of 
cells.(133) Immunofluorescence allows visualization of the fluorophore tagged cells, 
while they are still attached to plastic in cell culture, with a fluorescence microscope. 
The fluorescence is subjectively assessed and usually described as positive or 
negative.(134)  All three of these techniques can be highly useful techniques when the 
cell surface markers of interest are well known. 
 
 1.5.3.1 Antibody selection for flow cytometry and immunofluorescence 
 When selecting an antibody for protein detection it is important to select a 
species whose antibodies have affinity for the species of interest.(135) There are now 
many reagent companies that specialize in providing both monoclonal (MAbs) and 
polyclonal (PAbs) antibodies for thousands of different proteins.(136)  Antibodies that 
are induced by a variety of lymphocytes differentiating into plasma cells are known as 
polyclonal.  MAbs are produced by a single B lymphocyte clone.(137)  MAbs are much 
more difficult and time consuming to produce and are more expensive than PAbs.  The 
affinity of PAbs for a certain protein is often much higher than that of MAbs because 
PAbs recognize multiple epitopes.(136)  MAbs are easily deterred from attachment to 
their single epitope by conformational disturbances in the protein that effectively hide 
the epitope.(138)  However, the purity of a specific antibody is higher in monoclonal 
preparations. Therefore, if searching for a specific protein, it is imperative to properly 
denature the protein to straighten the polypeptide chain and reveal the epitope allowing a 
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MAb to attach.(137) With these appropriate conditions, MAbs are much more specific 
for a certain epitope and have very little cross-reactivity.(139) MAbs’ main advantage is 
their ability to be consistently produced from desired hybridoma while PAbs may 
change over time and are limited to the size and lifespan of the donor animal.(138, 140) 
Many laboratories have tried to create MAbs to surface markers specific to early 
osteoprogenitors or MSCs.(110, 135, 141) This is particularly challenging because no 
specific phenotypic features are known for absolute recognition of early 
osteoprogenitors at this time.  In efforts to elucidate this phenotype as described in this 
thesis, it was hypothesized that sorting the MSCs would enable isolation of the cells with 
characteristic surface antigens.  Then, identification of the cell surface markers would be 
less complicated and finally a study of their subsequent capacity for differentiation in 
vivo would be made possible.(84)   
 
1.6  A need for immuno-tagless sorting  
 There is no single, specific stem cell marker, because stem cells express a wide 
variety of surface antigens.(135) There is also no consensus on definitive equine MSC 
clusters of differentiation cell surface marker (CD marker) expression, as there is for 
humans,(77) which complicates using a traditional immunological tagging system such 
as fluorescence-activated cell sorting (FACS) to sort equine stem cells.(110) Also, 
presence of surface markers does not denote that MSCs are in a completely 
undifferentiated state.(132) Due to a lack of reactivity between commercial monoclonal 
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antibodies and epitopes on equine cells, phenotyping has been incomplete to date.(142)  
Sorting the MSCs with a tag-less method may avoid these CD marker issues. 
 While as a whole, MSCs are considered multipotent, some pluripotent 
subpopulations of MSCs have been identified in humans(143-145) and rats,(146) and 
found to have different shapes, proliferation and differentiation abilities.(146, 147) This 
indicates the importance of the identification and isolation of the fraction of MSCs that 
proliferates and differentiates optimally for the application of interest. 
 
1.7    Field-flow fractionation 
 Field-flow fractionation (FFF) refers to a group of bioanalytical techniques that 
have applications in the separation of bioanalytes ranging from proteins and nucleic 
acids to viruses, organelles and whole cells.(132) FFF techniques have been applied to 
cells to sort them by cell type,(148, 149) cell size,(150) for purification of cell 
culture,(151) to remove bacteria from bodily fluid,(152) and in conjunction with flow 
cytometry for cell characterization.(153) 
 
1.7.1 Gravitational field-flow fractionation  
 Gravitational field-flow fractionation (GrFFF) is decribed as a type of FFF 
technique that relies on gravity to achieve sedimentation, and has been used to sort B 
and T lymphocytes,(154, 155) red blood cells,(156, 157) and MSCs from blood and 
bone marrow.(158, 159)  MSCs differing in molar mass, size and surface antigens are 
driven by gravity into different velocity regions.(133) The cells are then carried 
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downstream through the channel at different speeds, and exit the channel after different 
retention times. The distribution of the cells into the various resulting fractions reveals 
the separation characteristics.(160) Traditional GrFFF systems then have a 
sedimentation step where an equilibrium between the gravitational field and the 
hydrodynamic forces of the transport fluid stream within the capillary channel is 
reached.(161) The resulting cell sedimentation in the system leads to cell adhesion to the 
wall of the capillary channel and cell–cell aggregation/stacking.  The adherent nature of 
multipotent MSCs exacerbates this aggregation and necessitates non-equilibrium earth 
gravity assisted dynamic fractionation (NEEGA-DF), which skips the sedimentation step 
and increases cell recovery.(133) 
 
1.7.2 Non-equilibrium GrFFF 
 Many aspects of the GrFFF technique make it ideal for use in cell culture.  
GrFFF allows for the expediting of MSC isolation by clearing other cells and 
contaminates from the early passage sample in a few hours instead of the weeks that can 
be spent performing the conventional method of adherence and detachment cycles. (158, 
162) The shortening of this clean-up phase would be of great use in clinical application 
of stem cell therapy as it would shorten the return time on samples received for injured 
patients.(133)  The GrFFF technology is similar to FACS in that it is a system to sort 
cells, but it is superior in several aspects. Currently FACS is the standard for sorting 
populations and subpopulations of cells.(133) The cells are tagged by antibodies and 
fluorescent labels in preparation for FACS thus changing their cell surface 
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characteristics and impeding post-FACS assays.(132) The use of immuno-tags for cell 
sorting is known to affect cell functionality.(160)  GrFFF is a tag-less system of stem 
cell sorting that will avoid cell surface antigen augmentation of the MSCs.(133) GrFFF 
is much more economical than FACS as it can be assembled in the laboratory from 
instruments that most biotechnology laboratories own.  GrFFF allows for the MSCs to 
be maintained under sterile conditions also allowing for further culture and expansion 
after fractionation.(132)  A more attainable cell sorting system is needed because the 
vast expense and technical difficulty of a FACS system are prohibitive to many.  To this 
end, the research described in this thesis used a non-equilibrium GrFFF separation 
mechanism to sort the MSCs.   
 
1.7.3 Limitations of GrFFF 
 The main limitation of using non-equilibrium GrFFF as a sorting system is the 
low number of cells that can be fractionated per run.(133) Some solutions have been 
elucidated. One group set up two GrFFF channels in parallel to increase sorting 
throughput,(159) and placed a coating on the PVC in the GrFFF system which improved 
the sample returns.(163) They also changed the shape of the chamber to a tube and ran 
samples in tandem.(164) 
 
1.8 Research objectives 
 The working hypothesis is that equine periosteum and skeletal muscle are 
equivalent, if not superior, multipotent sources of MSCs with osteogenic potential, 
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compared with results for the conventionally chosen donor tissues of fat and bone 
marrow.  The primary goal of this project was to identify the ideal equine donor tissue 
and subpopulation as a source of MSCs to promote bone healing.  To this end, the 
project had three objectives:   
  1. To confirm the ability to isolate, assess osteogenic capacities, and 
characterize mesenchymal stem cells (MSCs) from equine fat, bone marrow, periosteum, 
and muscle.   
  2. To sort the MSC populations, using non-equilibrium GrFFF, from two 
optimal tissues as determined in objective 1, and identify the MSCs subpopulations.   
  3. To identify those MSC subpopulations that express the highest 
osteogenic potential, and describe their phenotype.   
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2.1.  Abstract 
 The objective of this study was to characterize equine muscle tissue– and 
periosteal tissue–derived cells mesenchymal stem cells (MSCs) and assess their 
proliferation capacity and osteogenic potential in comparison with bone marrow– and 
adipose tissue–derived MSCs.  Cells were isolated from left semitendinosus muscle 
tissue, right distomedial tibial periosteal tissue, bone marrow aspirates from the fourth 
and fifth sternebrae, and adipose tissue from the left tail head subcutaneous region. 
Mesenchymal stem cells were characterized on the basis of morphology, adherence to 
polystyrene plastic, trilineage differentiation, and detection of stem cell surface markers 
via immunofluorescence and flow cytometry. Mesenchymal stem cells were tested for 
osteogenic potential with osteocalcin gene expression via real-time PCR assay.  
Mesenchymal stem cell cultures were counted at 24, 48, 72, and 96 hours to determine 
tissue-specific MSC proliferative capacity. Equine muscle tissue– and periosteal tissue–
derived cells were characterized as MSCs on the basis of spindle-shaped morphology, 
adherence to polystyrene plastic, trilineage differentiation, presence of CD44 and CD90 
cell surface markers, and nearly complete absence of CD45 and CD34 cell surface 
markers.  Muscle tissue–, periosteal tissue–, and adipose tissue–derived MSCs 
proliferated significantly faster than did bone marrow–derived MSCs at 72 and 96 hours. 
Equine muscle and periosteum are sources of MSCs. Equine muscle- and periosteal-
derived MSCs have osteogenic potential comparable to that of equine adipose- and bone 
marrow–derived MSCs, which could make them useful for tissue engineering 
applications in equine veterinary medicine.  
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2.2.   Introduction 
 Catastrophic breakdown is a major source of wastage in racehorses, with as 
many as 67%-89% of deaths attributed to exercise-related injury.(1-3)  Fractures account 
for 71% in UK, 88% in California, and 92.7% in Mid-west USA of fatal musculoskeletal 
injuries in racing Thoroughbreds.(1, 2, 4, 5) Because of their size and temperament, 
horses must bear weight on all limbs during the healing process. This leaves the surgical 
repair susceptible to failure because the constant loading of implants causes fatigue and 
ultimate mechanical failure of metal screws and plates.(6)  The requirement for constant 
loading combined with the fact that fractures heal much slower in horses than in other 
veterinary species(7)
 
leads to a guarded to poor prognosis for many equine fracture 
patients. If fracture healing rates could be increased, survival rates in affected horse may 
also increase, which would improve the animal welfare issue and make the initial fee for 
fracture fixation a more worthwhile investment to owners. Therefore, new methods to 
increase the rate of equine bone healing are needed and require research. 
 Studies
 
addressing the healing of equine musculoskeletal injuries through MSC-
based treatments, have shown that MSCs derived from amniotic membrane and bone 
marrow implanted into tendon lesions, have improved defect fill and decreased rate of 
re-injury.(8, 9) Mesenchymal stem cells are an option for clinical application because 
they can be effectively isolated and expanded with high efficiency.(10)  Mesenchymal 
stem cells can be cryopreserved, they maintain their viability, and later can be induced to 
differentiate along multiple lineages.(11, 12)  Although MSCs are being used clinically 
for certain musculoskeletal injuries, there are many unknown factors associated with 
their use, such as the ideal number of cells for transplantation, cell yield per gram of 
donor tissue, and ideal tissue source. Despite encouraging in vivo MSC treatment results 
45 
 
from equine soft tissue and joint injury studies
 
such as the improved healing 
characteristics of femoropatellar cartilage lesions(13), meniscal lesions(13, 14), tendon 
and ligament lesions(8), little is known about the efficacy of equine MSCs for 
regeneration of bone in vivo.(15, 16) 
 Identification of the optimal source of MSCs with the best osteogenic potential 
may prove critical for moving the basic science research toward clinical cell-based 
treatments to promote bone healing.(15)  Ideal tissue sources have been identified for 
human and rat MSCs on the basis of their intended use in vitro and in vivo,(17-20) and 
there is evidence that equine MSCs from bone marrow and fat have a high osteogenic 
potential, compared with that for MSCs from umbilical cord tissue and umbilical cord 
blood.(15, 21, 22) 
 Our laboratory group has identified periosteum and muscle tissues as sources of 
spindle-shaped, plastic-adherent cells able to undergo osteogenic differentiation.(23, 24)  
The working hypothesis of the group is that equine periosteum and skeletal muscle are 
equivalent, if not superior, multipotent sources of MSCs with osteogenic potential, 
compared with results for the conventionally chosen donor tissues of fat and bone 
marrow. 
 The purpose of the study reported here was to characterize equine muscle tissue– 
and periosteal tissue–derived MSCs, assess proliferative capacity of equine muscle- and 
periosteum-derived MSCs, and determine the osteogenic potential of equine muscle- and 
periosteum-derived MSCs in comparison with that of bone marrow– and adipose tissue–
derived MSCs.  
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2.3. Materials and Methods 
 2.3.1. Samples 
 Ten adult horses (2 to 5 years old) were used for postmortem collection of 
samples of bone marrow, periosteum, skeletal muscle, and adipose tissue. The horses 
were donated to the Atlantic Veterinary College for reasons other than this study and 
were euthanized in accordance with protocols approved by the University of Prince 
Edward Island Animal Care Committee. All horses were sedated with xylazine (1.1 
mg/kg, IV) and then euthanized via pentobarbital sodium injection (108 mg/kg, IV). All 
samples were collected immediately after horses were euthanized. 
 2.3.2. Bone marrow collection 
 A 10-cm-wide band overlying the sternum was clipped of hair.  The skin over the 
fourth and fifth sternebrae was aseptically prepared, and a bone marrow biopsy needle 
(Carefusion, San Diego, CA) was used to obtain a bone marrow aspirate from the fourth 
sternebrae. The aspirate (9.5 mL) was collected into a 12-mL syringe that contained 2.5 
mL of heparin (1,000 U/mL). Another aspirate was immediately obtained from the fifth 
sternebra in the same manner. 
 2.3.3. Adipose, muscle, and periosteum collection 
 The area left lateral to the base of the tail, the area superficial to the left 
semitendinosus and semimembranosus muscles, and the distomedial aspect of the right 
tibia were aseptically prepared. Skin incisions were made, and underlying tissues were 
harvested and approximate sizes and weights are as follows. A 24-cm
3
 (3-g) section of 
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adipose tissue was harvested from the subcutaneous tissues over the gluteal muscles in 
the region of the base of the tail. A 9-cm
3
 (6-g) section of muscle was dissected and 
harvested from the left semitendinosus muscle. A 4-cm
2
 (0.5-g) section of periosteum 
from the medial surface of the proximal portion of the right tibia was elevated and 
harvested. The amount of sample collected was considered consistent with a clinically 
feasible biopsy specimen that would not result in adverse effects. The tissues collected 
were placed in α-MEM and transported to our laboratory. 
 2.3.4. Cell isolation from bone marrow 
 Cells were isolated from bone marrow via a centrifugation gradient technique. 
The samples were centrifuged in 50-mL tubes at 1,500 X g for 10 minutes. The buffy 
coat then was collected and placed into standard medium, which was composed of α-
MEM supplemented with 10% fetal bovine serum, (PAA Laboratories Inc, Etobicoke, 
ON) L-glutamine (2mM), 10,000 U of penicillin and 10 mg of streptomycin/mL, and 
amphotericin B (250 µg/mL). This standard medium was maintained the same for the 
bone marrow and the other 3 tissues. 
 2.3.5. Fat, muscle, and periosteum cryopreservation 
 Fat, muscle, and periosteum were collected from each horse and placed in 
separate vials of chilled α-MEM solution. Tissues were processed within 24 hours after 
collection. Tissues that were not processed immediately were kept on ice and 
refrigerated at 4°C for 12 hours and then processed. Cold, sterile PBS solution was 
placed in Petri dishes to provide a moist environment for tissues subsequently cut into 1-
cm segments. Tissue segments were placed into 2-mL cryovials and submerged in 
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freezing medium composed of 92.5% PBS solution and 7.5% dimethyl sulfoxide. The 
cryovials remained at room temperature (approx 20°C) for 30 minutes to allow the 
freezing medium to penetrate the tissue. The samples were then placed in closed-cell 
extruded polystyrene foam containers and stored in a –80°C freezer for a minimum of 24 
hours. All samples were placed into a –196°C liquid nitrogen tank within 72 hours after 
processing.(25)  
 2.3.6. Fat, muscle, and periosteum cell isolation 
 Cells were isolated from fat, muscle, and periosteum by means of an enzyme 
digestion technique. Cryopreserved adipose and muscle tissues were warmed in a water 
bath (37°C) for approximately 5 minutes until the liquid was thawed. Tissue handling 
was performed via sterile technique in a biosafety cabinet. Each tissue was removed 
from the cryovials and placed in a 50-mL centrifuge tube that contained 25 mL of sterile 
PBS solution. The tissue was rinsed with PBS solution, weighed, and minced. Minced 
tissue was placed in centrifuge tubes that contained 10 mL of collagenase type I 
(Invitrogen, Toronto, ON) (2,000 units/mL); tubes then were mixed via a vortexer and 
placed in a 37°C incubator. The tubes were mixed via a vortexer every 20 minutes for 60 
minutes. Once the tissue was digested, 10 mL of standard medium was added to the 
mixture to inhibit further enzymatic digestion. The cell suspension was filtered through a 
100-µm filter and then a 70-µm filter and then was centrifuged at 377 x g for 10 
minutes. Supernatant was removed, and the cell pellet was resuspended in standard 
medium. Viable cell numbers, as determined on the basis of 0.4% trypan blue dye 
exclusion, were counted with a hemacytometer. Viable adipose tissue and muscle cells 
were plated in T-75 flasks at a cell density of 33 X 10
3
 cells/cm
2
 in standard medium. 
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Cell cultures were maintained in a humidified incubator with 5% CO2 and 95% air at 
37°C. 
 Isolation of cells from the periosteum was similar to that of adipose tissue and 
muscle, except that the minced tissue was pretreated by incubation with type I 
collagenase (2,000 U/mL) for 10 minutes. The partially digested tissue was rinsed and 
treated by incubation with type I collagenase (2,000 U/mL) for an additional 160 
minutes. Viable periosteal cells were plated in T-75 flasks at a cell density of 33 X 10
3
 
cells/cm
2
 in standard medium. 
 2.3.7. Cell culture and cell passage 
 Cells adhered to the flasks by 24 to 48 hours (start of culture was designated as 
time 0); unattached cells were washed from the flasks with PBS solution. Medium was 
changed 3 times/wk. Cells were maintained in this environment until confluence, but 
culture did not exceed 9 days. 
 At each passage, cells were detached with 0.25% trypsin-EDTA. Cells were  
counted and viability determined with 0.4% trypan blue dye. First-passage cells from 
each tissue of each horse were used for a proliferation assay and to culture a second 
passage with higher cell counts. Second-passage cells from each tissue of each horse 
were used for a second proliferation assay and characterization assays at the various cell 
densities. 
 2.3.8. Characterization of MSCs and cell differentiation 
 Cells from each tissue were maintained for 1 week in standard medium. After 
this period, adherence to the flask and spindle-shaped morphology were confirmed. 
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 Cells from each tissue from each of 3 horses were induced to differentiate into 
adipocytes, chondrocytes, and osteoblasts. Each of the 3 lineages was cultured in parallel 
with the same cells in standard medium as described. Light microscopy (Axiovert 40 
CFL, Carl Zeiss Canada Ltd, Toronto, ON) digital images (Power shot G5, Canon, 
Mississauga, ON) were obtained at various times representative of the different 
morphologies. Histochemical analysis and morphology were used to confirm 
differentiation into the 3 lineages. 
 
 2.3.9. Adipogenic differentiation 
 Cells were seeded at a density of 12,000 cells/cm
2
 into chamber slides (Becton-
Dickinson, Falcon Bedford, MA).  Cells initially were cultured in standard medium for 3 
days. Thereafter, cells were incubated with an adipogenic induction medium (Dulbecco 
modified Eagle medium and F12, 3% fetal bovine serum, 10,000 U of penicillin, and 10 
mg of streptomycin/mL, amphotericin B (250 µg/mL), biotin (Sigma, Oakville, ON) (33 
µmol/L), pantothenate (Sigma, Oakville, ON) (17 µmol/L), insulin (1 µmol/L), 
dexamethasone (1 µmol/L), isobutylmethylxanthine (IBMX, Sigma, Oakville, ON) (0.5 
mmol/L), rosiglitazone (Toronto Research Chemicals, Toronto, ON)
 
(5 µmol/L), and 5% 
rabbit serum (Invitrogen, Toronto, ON)) for 2 days. The same medium without 
isobutylmethylxanthine and rosiglitazone then was used to maintain the adipocyte cell 
culture until day 7, when the cells were fixed for 20 minutes in 10% formalin at room 
temperature and stained for neutral lipid accumulation with oil red O to indicate 
adipogenic differentiation.(21)  
 2.3.10. Chondrogenic differentiation 
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 Cells were seeded at a density of 500,000 cells/15 mL in polypropylene conical 
tubes and were then centrifuged (500 X g for 5 minutes) into pellets, which were 
supplemented with a chondrogenic differentiation medium (Hams 12; dexamethasone 
(10
-7
M); culture supplement containing bovine insulin, transferrin, selenious acid, 
linoleic acid, and BSA, (ITS+1, Sigma, Oakville, ON) 5% fetal calf serum, 10,000 U of 
penicillin and 10 mg of streptomycin/mL, amphotericin B (250 µg/mL), ascorbic acid 
(50 µg/mL), and recombinant human transforming growth factor-β 1 (rhTGF-beta 1, 
Millipore, Temecula, CA) (11 ng/mL)).  Pellet cultures were maintained for 21 days. 
Pellet cultures were performed in parallel with standard medium and chondrogenic 
medium, with no growth factor as a control culture. After culture for 21 days, 
differentiated pellets were fixed in 10% formalin for 24 hours, dehydrated in a graded 
series of ethanols, and embedded in paraffin.  A microtome (Leica RM 2245, Leica 
Microsystems, Richmond Hill, ON) was used to make sections (thickness of 5 µm) that 
were then stained with Alcian blue (pH, 1.0) for the detection of cartilage-specific 
proteoglycans to confirm chondrogenic differentiation.(26)  
 2.3.11. Osteoblastic differentiation 
 Cells were seeded at a density of 12,000 cells/cm
2
 into chamber slides. Cells 
were supplemented with an osteogenic induction medium (α-MEM, 5% fetal calf serum, 
10,000 U of penicillin, and 10 mg of streptomycin/mL, amphotericin B (250 µg/mL), 
ascorbic acid (50 µg/mL), dexamethasone (10
-8
M), and β-glycerophosphate (10mM)). 
Cultures were maintained for 7 days and then fixed for 20 minutes in 10% formalin at 
room temperature.(24)  Cultures were then stained with von Kossa stain(26) for the 
detection of calcium and with the substrate naphthol AS MX-PO4 and Red Violet LB 
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salt(27) for the detection of alkaline phosphatase to confirm mineralization and 
osteoblastic differentiation. 
 2.3.12. Immunofluorescent analysis for MSC surface markers 
 Cells from each tissue from each of 3 horses were plated at 2,500 cells/cm
2
 in 
standard medium. Cells were then incubated at 37°C for 24 hours in a humidified 
incubator at 5% CO2 and 95% air. Culture medium was removed and cells were washed 
twice with PBS solution. Cells were fixed in 4% paraformaldehyde (pH, 7.4) for 15 
minutes. Paraformaldehyde was removed and cells were washed twice with PBS 
solution. Cells were blocked by incubation with 1% BSA in PBS solution at room 
temperature for 1 hour. The blocking solution was then removed and the remaining steps 
were conducted in a dark room. One microliter of antibodies (CD34 (AbD Serotec, 
Raleigh, NC), CD44 (Abcam Inc, Cambridge, MA), CD45 (AbD Serotec, Raleigh, NC), 
CD90 (Accurate Chemical and Scientific Corp, Westbury, NY), CD105 (Chemicon 
International, Billerica, MA), and CD146 (Millipore, Billerica, Mass); FITC was the 
fluorochrome for CD34, CD44, and CD45 and Alexa Fluor 88 was the fluorochrome for 
CD 146) diluted in 1% BSA in PBS solution were added to the cells, and plates were 
incubated overnight at 4°C. The next day, cells marked with the CD90 antibody were 
washed twice with PBS solution, and FITC-labeled secondary antibody (Goat anti-
mouse IgG FITC-labeled antibody, Cedarlane Laboratories Ltd, Burlington, ON) diluted 
in 1% BSA in PBS solution was added. Cells were then maintained at room temperature 
for 1 hour. All cells were covered with PBS solution and allowed to sit for 5 minutes at 
room temperature in dark conditions; this process was repeated with fresh PBS solution 
3 times. A nucleic acid stain (Hoechst 33258, Invitrogen, Toronto, ON) (1µM of stock 
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solution/10 mL of distilled water) was added to all cells; cells were incubated for 1 
minute and then washed once with PBS solution. Cells remained in PBS solution, and 
digital images were obtained immediately. Cells from each of the tissues were evaluated 
for positive results for MSC surface markers. 
 2.3.13. Flow cytometric analysis of MSC surface markers 
 Cultured and expanded cells from the second passage of each of the 4 tissues 
(bone marrow, fat, periosteum, and muscle) from 1 horse were used for the flow 
cytometric analysis. The amount of antibody was optimized with a cytometer 
(FACSAria flow cytometer, BD Biosciences, Mississauga, ON). 
 Cells were washed with PBS solution and then incubated for 15 minutes in a 
humidified incubator at 5% CO2 and 95% air at 37°C with a mixture of versene 
(Invitrogen, Toronto, ON) and trypsin (5:1). This detachment method yielded the highest 
values for viability (up to 95% after 8 hours). The reaction was stopped with an equal 
amount of standard medium. The cell suspension was centrifuged (377 X g for 10 
minutes), and the pellet then was resuspended and washed in ice-cold 1% BSA in PBS 
solution. The cell suspension was again centrifuged (377 X g for 10 minutes), and the 
resulting pellet was resuspended in ice-cold 1% BSA in PBS solution, stained with 
trypan blue to determine viability, and counted for flow cytometric analysis. 
 One million cells per sample were labeled. Sample 1 was unstained and served as 
a negative control sample. Samples 2 to 5 were labeled with validated(28, 29) antibodies 
(CD45, CD44, CD90, and CD34, respectively). Sample 6 was labeled with a 
combination of 45 allophycocyanin (AbD Serotec, Raleigh, NC), 44 R-phycoerythrin 
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(Biolegend, San Diego, CA), and 90 FITC (Accurate Chemical, Westbury, NY).  
Sample 7 was labeled with a combination of 34 allophycocyanin, 44 phycoerythrin, and 
90 FITC. One million cells were collected and centrifuged (377 X g for 10 minutes), and 
primary antibodies were added in 1% BSA in PBS solution (Table 2.1). Samples were 
placed on ice and incubated for 45 minutes; samples then were washed in ice-cold 1% 
BSA in PBS solution and centrifuged (377 X g for 10 minutes). The washing and 
centrifugation steps were repeated 3 times. Cells were stored at 4°C until flow 
cytometric analysis. The secondary antibody for CD90 was diluted in 1% BSA in PBS 
solution and incubated on ice for 30 minutes and then washed in ice-cold 1% BSA in 
PBS solution and centrifuged (377 X g for 10 minutes). The washing and centrifugation 
steps were repeated 3 times. Cells were stored at 4°C until flow cytometric analysis 
(Aurum total RNA mini kit, Bio-Rad Laboratories, Hercules, CA). 
Table 2.1 Characteristics of antibodies used for flow cytometric analysis of MSC surface 
markers. 
                
 
 
 2.3.14. Proliferation assay and MSC yield 
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 Cells from each tissue from each of the 10 horses were plated (in triplicate) in 
35-mm wells at 3,000 cells/cm
2
. The cells were detached with trypsin and counted at 24, 
48, 72, and 96 hours with a hemacytometer to determine the proliferation rate and 
doubling time. The procedure was repeated for the first and second passage of each 
tissue. 
 At the first passage, data were collected from the 10 horses to determine the 
mean MSC yield (MSCs obtained per gram of tissue) for bone marrow, adipose tissue, 
muscle, and periosteum.  The volume of bone marrow and weight of the 3 other tissues 
were recorded during the isolation and culture procedures.  Equine bone marrow has a 
mass density of 1 g/mL.(25)  Therefore, the bone marrow volumes were converted to 
weights for ease of comparison with results for the other 3 tissues. 
 2.3.15. Osteogenic assay 
 Cells from the second passage of all 10 horses and all 4 tissues were seeded in 6-
well plates at 200 cells/cm
2
.  Half of the wells were induced with osteogenic medium, 
and the other half were maintained in standard medium to serve as control cultures. 
Growth of one group of the paired cultures was stopped on day 7, and the other was 
stopped on day 10. Total RNA was extracted (Aurum total RNA mini kit, Bio-Rad 
Laboratories, Hercules, CA) from the cells.  The cDNA was synthesized from total RNA 
via a cDNA synthesis kit (iScript cDNA synthesis kit, Bio-Rad Laboratories, Hercules, 
C).  Primers derived from the coding regions of osteocalcin were as follows:  forward, 
5’-CTGGGCCAGGACTCCGCATCT-3’; and reverse, 5’-
AGCCAGCTCGTCACAGTCTGGGTTG-3’. Expression of the osteocalcin gene was 
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quantified via real-time PCR assay with a mix (iQ SYBR Green Supermix, Bio-Rad 
Laboratories, Hercules, CA).  The PCR assay was performed on a thermal cycler 
(Rotorgene-6 RG 3000, Corbett Research, Montreal, QC).  Cycling conditions were as 
follows: 95°C for 5 minutes; 35 cycles of 95°C for 15 seconds, 56°C for 30 seconds, and 
72°C for 45 seconds; and melting from 55° to 99°C.  Nuclease-free water instead of 
cDNA was used as a negative control sample. Gene expression was determined via the 
comparative cycle threshold (ΔΔCT) method.(30)  The housekeeping gene 
glyceraldehyde 3-phosphate dehydrogenase was used to normalize the expression of 
each osteocalcin gene.(31, 32)  
 2.3.16. Statistical analysis 
 Statistical analysis of proliferation data was conducted with a linear mixed model 
on logarithmically transformed outcomes with fixed effects of tissues, passages (first 
and second), and time (24, 48, 72, and 96 hours) as well as all interactions and random 
effects of horses, tissues within horses, passages within tissues, and sets of triplicates for 
each of the time points. Pairwise comparisons between tissues within time points 
underwent a Holm adjustment for multiple testing.(33)  An additional analysis with an 
assumed linear effect of time was used to estimate doubling times for each of the tissues. 
Statistical analysis of osteocalcin gene expression measured with a real-time 
PCR assay was conducted via a 2-way ANOVA with effects of tissues and horses, after 
square root transformation of the normalized cycle threshold values to comply with 
model assumptions P< 0.05. Data for days 7 and 10 were analyzed separately. Tissues 
were compared for their expression of osteocalcin with that of the standard medium via 
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t-tests on the basis of least squares means. Pairwise comparisons among tissues were 
conducted with the Tukey method P<0.05. 
 Statistical software was used for the analysis of proliferation data (SAS, version 
9.2, SAS Institute Inc, Cary, NC) and osteocalcin data (Minitab, version 16, Minitab Inc, 
State College, PA).  Significance was set at values of P < 0.05. 
2.4. Results 
 2.4.1. Characterization of MSC morphology, adherence, and confluence 
 Cells isolated from all 10 horses and all 4 tissues developed a spindle-shaped 
morphology and readily adhered to polystyrene plastic. The MSC cultures derived from 
muscle, periosteum, and adipose tissue became 80% to 100% confluent within 6 to 8 
days after initial seeding of flasks in the first passage. However, MSC cultures derived 
from bone marrow consistently required longed to achieve confluence and only achieved 
45% to 75% confluence during this time. 
 2.4.2. Differentiation 
 Cells isolated from 3 horses and all 4 tissues were capable of trilineage 
differentiation (Figure 2.1).  Cells cultured in adipogenic differentiation medium for 4 
days had positive results for oil red O staining of lipid droplets.  Cells cultured in 
standard medium did not develop lipid droplets and lacked staining with oil red O. 
Pelleted MSCs cultured in chondrogenic differentiation medium for 21 days had cells 
within lacunae in Alcian blue–stained material.  Cells cultured in standard medium did 
not have lacunae and lacked staining with Alcian blue. 
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Figure 2.1—Representative photomicrographs of histochemical staining for MSCs 
cultured from equine bone marrow (BMSC), adipose tissue (AMSC), periosteum 
(PMSC) and muscle (MMSC). Standard medium (SM) is unstained, osteogenic medium 
(OM) is stained with von Kossa stain, adipogenic medium (AM) is stained with oil red 
O, and chondrogenic medium (CM) is stained with Alcian blue. Bar = 200 µm. 
 
 Cells cultured in osteogenic differentiation medium for 7 to 10 days formed bone 
nodules based on positive results of alkaline phosphatase and calcium specific stains. 
Cells cultured in standard medium did not develop nodules and lacked staining for 
alkaline phosphatase and calcium. 
 2.4.3. Immunofluorescent analysis of CD markers 
 Cells isolated from 4 horses and all 4 tissues cultured via standard conditions in 
the first passage strongly expressed the cell surface antigen CD90 and weakly expressed 
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CD44, as determined on the basis of immunofluorescence. None of the isolated cells had 
immunofluorescence for CD45, CD34, CD146, or CD105 (Figure 2.2). 
 
Figure 2.2—Representative images of immunofluorescence labeling of muscle-derived 
MSCs cultured from horses and stained for cell surface markers. Notice the weak 
staining for CD44, strong staining for CD90, and absence of staining for CD45. Bar = 
200 µm. 
 2.4.4. Flow cytometric analysis 
 Cells isolated from 1 horse and all 4 tissues that were cultured via standard 
conditions in the second passage expressed high amounts of the cell surface antigens 
CD90 and CD44 and expressed extremely low amounts of CD45 and CD34, as 
determined on the basis of flow cytometric data (Figure 2.3; Table 2.2). 
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Figure 2.3—Results of flow cytometric analysis of MSCs cultured from equine muscle 
(A), periosteum (B), bone marrow (C), and adipose tissue (D) and stained for detection 
of CD90 and CD44 expression. Percentage values indicate the number of cells within 
each quadrant.  The upper right quadrant contains +CD44 and +CD90 cells.  The upper 
left quadrant contains +CD44 and –CD90 cells.  The lower left quadrant contains –
CD44 and –CD90 cells.  The lower right quadrant contains –CD44 and +CD90 cells.  
The fluorescence intensity (arbitrary units) is depicted. 
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Table 2.2—Expression and coexpression of CD markers for each tissue obtained from 1 
representative horse. 
          
 2.4.5. Proliferation rate 
 Analysis of the logarithmically transformed MSC counts revealed a significant 
(P < 0.001) interaction between tissues and times, whereas no significant effects were 
detected for passages (including interactions). At 72 and 96 hours, muscle-, periosteum-, 
and adipose-derived MSCs proliferated significantly faster than did bone marrow–
derived MSCs (Figure 2.4). Assuming a log-linear effect of time (equivalent to assuming 
a constant doubling rate) yielded estimated doubling times for MSCs derived from bone 
marrow (27.3 hours), periosteum (15.0 hours), muscle (13.8 hours), and adipose tissue 
(16.2 hours). All pairwise comparisons between doubling times yielded significant 
results, except for periosteum-derived MSCs, compared with results for muscle- or 
adipose-derived MSCs. The model without assumed linearity of time yielded a 
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significantly (P = 0.01) better fit for the data and was thus preferred for reporting 
purposes. 
                           
Figure 2.4— Graph of model-based estimated median cell counts of MSCs versus time 
after start of culture for MSCs derived from equine muscle (▲), periosteum (■), adipose 
tissue (♦), and bone marrow (●).  Start of MSC culture was designated as time 0.  
*Within a time point, value for bone marrow differs significantly (P = 0.01) from the 
values for all other tissues. 
 2.4.6. MSC yield 
 Periosteum provided a higher MSC yield than did the other 3 tissues. Periosteum 
yielded a mean of 30.3 million cells/g of tissue, muscle yielded 642,000 cells/g of tissue, 
adipose tissue yielded 1.7 million cells/g of tissue, and bone marrow yielded 83,000 
cells/g of tissue. 
 2.4.7. Real-time PCR assay for osteocalcin expression 
 Osteogenic capacity determined on the basis of gene expression of osteocalcin 
was measured in all 4 tissues from all 10 horses. Muscle-, periosteum-, adipose-, and 
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bone marrow–derived MSCs all had significantly higher osteocalcin expression on day 7 
after differentiation with osteogenic medium than did the control samples cultured in 
standard medium. There was no significant (P = 0.17) difference in osteocalcin 
expression among the tissues. There were no significant differences between 
differentiated and nondifferentiated cultures of MSCs on day 10 (Figure 2.5). 
                    
Figure 2.5—Mean ± SD results of nontransformed data for real-time PCR assay of 
osteocalcin gene expression for MSCs derived from 4 tissues obtained from 10 horses 
and cultured for 7 (gray bars) and 10 (black bars) days. *Within a tissue, value differs 
significantly (P < 0.05) from the baseline number of MSCs cultured in standard medium 
(horizontal black line).  GAPDH = Glyceraldehyde 3-phosphate dehydrogenase. BM= 
Bone marrow; M= Muscle; P= Periosteum; F= Fat. 
2.5. Discussion and Conclusions 
 Analysis of results of the present study confirmed that cells derived from equine 
muscle and periosteal tissues can be characterized as MSCs, equine muscle- and 
periosteum-derived MSCs have superior proliferative capacity to that that of bone 
marrow–derived MSCs, and equine muscle- and periosteum-derived MSCs have 
osteogenic potential comparable to that of equine adipose- and bone marrow–derived 
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MSCs. In this study, equine muscle and periosteal tissues were sources of MSCs, as 
determined by morphology, adherence to plastic, trilineage differentiation, and detection 
of stem cell surface markers with immunofluorescent and flow cytometric analyses. 
 Muscle and periosteum are good sources of MSCs in rats(18) and dogs,(25) but 
only muscle has been validated as a source of MSCs in horses.(34)  In humans, the 
importance of muscle-derived MSCs(35)
 
and periosteum-derived MSCs in bone repair 
(36, 37) have been reported. Therefore, it appears reasonable that muscle and periosteum 
may be useful sources of MSCs in horses as well. Muscle-derived MSCs have been 
isolated from horses and evaluated for potential tendon differentiation,(34) and 
periosteum-derived MSCs have been isolated from horses and evaluated for their 
potential osteogenic differentiation.(24)  However, muscle- or periosteum-derived MSCs 
have not been thoroughly characterized as MSCs. 
 We used post-mortem collected tissues due to the fact we were collecting 
multiple tissues from multiple animals, and the animals available for the collection of 
tissues were horses admitted for elective euthanasia. Cell viability from tissues obtained 
immediately after death had viability approaching 90% and maintained good viability 
throughout the study similar to a previous study in dogs where postmortem tissues were 
used.(25)  
The rationale for cryopreserved whole tissue sections was to preserve samples 
for later stem cell recovery. Immediate cryopreservation of tissues was considered more 
practical than direct primary isolation of stem cells, which requires additional equipment 
and personnel. Cryopreservation techniques may be advantageous for banking of 
specimens from which MSC cultures are not immediately needed. This is supported by  
three studies(38-40)
 
in humans in which found that cells isolated from tissue processed 
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and frozen with cryopreservation medium and subsequently thawed maintained 
morphological and developmental competence and had MSC-hallmark trilineage 
differentiation with appropriate culture conditions. The buffy coat of the bone marrow 
does not survive cryopreservation procedures well and was therefore cultured 
immediately after collection from the horses of the present study. 
 Equine MSCs derived from bone marrow and adipose tissue MSCs have been 
characterized on the basis of morphology, adherence to plastic, trilineage differentiation, 
and CD markers,(41-43) and results of the present study confirmed those findings. In 
addition, cells isolated and expanded from muscle and periosteal tissues were 
characterized as MSCs on the basis of the identical criteria accepted for equine MSC 
characterization. 
 Characterization with immunofluorescent staining revealed strong expression of 
the cell surface antigen CD90 for cells of all tissues, which indicated the cells were 
MSCs. Slight weakness of CD44 expression could have been attributable to sensitivity 
to the proteolytic action of trypsin, which is the agent most commonly used to detach 
cells during cell culture.(44)  Another explanation of the slightly weaker staining for 
CD44 is that direct immunolabeling was used to detect CD44, but an indirect 
immunolabeling method, which is more sensitive, was used to detect CD90.(45) In 
addition, there can be variations in expression of cell surface markers on the basis of 
differences in culture times and isolation techniques.(46, 47)  None of the isolated cells 
stained for CD45, CD34, CD146, or CD105, which is consistent with findings for equine 
MSC surface markers in another study.(42)  
 Characterization with immunophenotyping also revealed that cells from 
periosteum and muscle as well as those from fat and bone marrow could be 
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characterized as MSCs. Although there is currently no definitive consensus for 
expression of CD markers of equine MSCs,(28) findings in the present study match 
those of other studies that were positive for the expression of cell surface markers CD90 
and CD44(48, 49) and low or negative expression of CD34 and CD45.(42)  
 To our knowledge, this is the first study conducted to characterize equine 
muscle- and periosteum-derived MSCs as defined on the basis of dual expression of 
CD44 and CD90 and extremely low expression of CD34 and CD45. Interestingly, for 
each of the 4 tissues, the percentages of cells with dual expression of CD90 and CD44 
were extremely close to those with single positive staining for each cell surface marker, 
and the relatively high percentages indicated a reasonably pure population of MSCs 
from each tissue. Bone marrow–derived MSCs had a lower percentage of dual staining 
cells in all 4 tissues, which confirmed that the concentration of MSCs was lower in bone 
marrow than in the other 3 tissues. 
 Analysis of data from the present study revealed that bone marrow–derived 
MSCs proliferated slower than did muscle-, periosteum-, and adipose-derived MSCs. 
This is consistent with previous findings that muscle-derived cells yield greater cell 
culture numbers in a shorter time than do bone marrow–derived cells.(21, 34)  
 Bone marrow may not be the optimum tissue for use in bone healing when time 
to culture clinically useful numbers of autogenous cells is considered. Bone marrow–
derived MSCs also senesce much earlier than do other MSCs of horses.(50)  The slow 
proliferation of bone marrow–derived MSCs could have been attributable to the low 
number of proliferative cells in bone marrow aspirates. On the basis of a CFU fibroblast 
assay, the frequency of MSCs in the mononuclear cell fraction of equine marrow is 
reported to be 1 in 4.2 X 10
3
 cells and to differ among horses by 10-fold.(43)  The small 
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fraction of proliferative cells among the total cell isolates could be to blame for the 1 to 
2 weeks of extra expansion time needed for bone marrow–derived MSCs over the 
expansion time needed for other sources of MSCs.(51, 52)  This points to the need for a 
cell-sorting method to isolate this small proliferative fraction of cells before culture, 
which would aid in the removal of contaminant cells that physically impede MSC 
adherence and thereby hasten the expansion process. 
 Periosteum provided a higher MSC yield than did the other 3 tissues. Periosteum 
yielded a mean of 365 times as many MSCs/g of tissue then did bone marrow at the end 
of passage 0. Although the exact dose of MSCs for various injuries has yet to be 
determined, there is evidence that MSC effect is a dose-dependent phenomenon.(53-55)  
It is clinically important to use stem cell sources that are extremely proliferative because 
treatment is dependent on the number of cells in cultures, and up to 70 million 
osteoblasts may be required to generate 1 cm
3
 of bone.(56)  
 In addition, ease of harvest, quantity of donor tissue available, and morbidity at 
the donor site are clinically important issues. The general requirement for treatment with 
stem cells is that the cells be from a readily available source and there is low morbidity 
associated with donor harvest. Muscle tissue, which can be readily harvested (similar to 
adipose tissue), meets these criteria. Harvest of bone marrow from the sternebrae is more 
difficult and can be associated with the risk of entering the thoracic cavity and 
potentially puncturing the pericardium when attempting aspiration  from the 
sternum.(57, 58)  The temperament of the horse as well as the expertise of the 
veterinarians harvesting the bone marrow are risk factors associated with this method of 
harvest. Methods to optimize and improve the safety of bone marrow harvest by 
ultrasound guidance of aspirate needle into the 4-6
th
 sternebrae have recently been 
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recommended and shown effective.(59)  Bone marrow can also be harvested from the 
tuber coxae to avoid the risk associated with aspiration from the sternum; however, a 
recent study(60) found reduced numbers of MSCs for aspiration of the tuber coxae, 
compared with results for aspiration of the sternum in middle-aged horses. Periosteum 
was relatively easy to harvest as well, but horses would likely need to be anesthetized. 
Harvest would be clinically feasible at the time of fracture repair because it only requires 
removal of a 4-cm
2
 section of periosteum from the fracture site or a remote donor site. 
 In the present study, we determined that equine muscle and periosteal tissues are 
donor sources of MSCs that have osteogenic potential for bone healing. It is unlikely 
that a single donor source of MSCs will be superior for regeneration of tissue from all 
different germ layers.(61)  In one in vitro study,(21) adipose-derived MSCs required 
longer than did bone marrow–derived MSCs to undergo osteogenic induction, and 
investigators in another in vitro study(15) found that bone marrow–derived MSCs 
required longer to undergo osteogenic induction and had more osteogenic potential than 
did adipose-derived MSCs. Therefore, there is a need for research on which donor 
tissues are most suitable for use in bone healing and we plan to address this in the future. 
 Real-time PCR assay for osteocalcin expression was used in the present study to 
confirm osteoblastic differentiation.(62, 63)  Osteocalcin is an abundant noncollagenous, 
hydroxyapatite-binding protein found in bone that is commonly measured and is a 
specific marker for the osteoblastic stage of osteogenesis.(19, 35)  Mesenchymal stem 
cells from all 4 tissues could be induced to differentiate into the osteoblastic lineage, as 
indicated by an increase in osteocalcin expression measured on day 7.  Mesenchymal 
stem cells from day 10 had no significant differences between differentiated and 
nondifferentiated cultures, which indicated a decrease in osteocalcin expression between 
69 
 
day 7 and 10, which is consistent with a temporal sequence of osteogenic 
differentiation.(64)  
 One of the limitations of the present study was the use of a hemacytometer for 
cell counts. Automated cell counters may have a lower error margin, but we adhered to 
research protocols that involved the use of hemacytometers.(21, 37, 41)  All counts were 
performed in triplicate for each sample to improve accuracy. Another limitation of the 
study was that counts of MSCs per gram of tissue did not address heterogeneity of the 
tissue. However, it is a repeatable and acceptable method(25, 65, 66) to measure and 
compare cell yield from tissues because a weight measurement is more easily made and 
more accurate than is a size measurement. Finally, these measurements were paired with 
clinically feasible sizes of biopsy specimens for practical application. Another limitation 
of this study was the use of a single osteoblastic marker. Evaluation of the expression of 
additional genes as osteoblast markers may have highlighted differences in osteogenic 
potential among tissues, considering that no significant differences were detected with 
use of 1 marker.(67) Because the focus of this study was to confirm osteogenic 
differentiation as part of trilineage differentiation, osteocalcin was used as the sole 
marker.(62, 63)  Finally, although there was no significant difference (P = 0.17) in 
osteocalcin expression among the 4 tissues of the 10 horses, it is possible that an 
increased number of horses may yield data in which the differences are significant. 
 In humans, periosteum and muscle clearly are potent sources of bone-forming 
cells for use in orthopedic repair.(35, 36)  To our knowledge, the study reported here is 
the first to confirm osteocalcin expression in equine muscle- and periosteum-derived 
MSCs, which indicates their osteogenic potential. The characterization of muscle- and 
periosteum-derived MSCs broadens the choices available to clinicians who use MSCs in 
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cell-based treatments, and MSCs from these tissues show much promise for future 
application in cell-based treatment for use in bone healing in horses. 
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3. APPLICATION OF A NOVEL MESENCHYMAL STEM CELL SORTING 
SYSTEM FOR EQUINE MESENCHYMAL STEM CELLS
1 
 
 
3.1. Abstract 
 The objective of this study was to validate non-equilibrium gravitational field-
flow fractionation (GrFFF), an immunotag-less method of sorting mesenchymal stem 
cells (MSCs) into subpopulations, for use with  equine muscle tissue-derived, periosteal 
tissue-derived, bone marrow-derived, and adipose tissue-derived mesenchymal stem 
cells.  Cells were isolated from left semitendinosus muscle tissue, periosteal tissue from 
the distomedial aspect of the right tibia, bone marrow aspirates from the fourth and fifth 
sternebrae, and left supragluteal subcutaneous adipose tissue of 6, adult horses.  Aliquots 
of 800 x10
3
 MSCs from each tissue source were separated and injected into a ribbon-like 
capillary device by continuous flow (GrFFF proprietary system).  Cells were sorted into 
6 fractions and absorbencies (OD) were read.  Six fractions from each of the 6 aliquots 
were then combined to provide pooled fractions that had high enough cell numbers to 
seed at equal concentrations into assays.  Equine muscle tissue-derived, periosteal tissue-
derived, bone marrow-derived, and adipose tissue-derived mesenchymal stem cells were 
consistently sorted into 6 fractions that remained viable for use in further assays.  
Fraction one had a more cuboidal morphology in culture when compared to the other 
fractions.  Statistical analysis of the fraction absorbencies (OD) revealed a significant 
difference (P-value of <0.05) when fraction 2 and 3 were compared to fractions 1, 4, 5, 
and 6.  Non-equilibrium GrFFF is a valid method for sorting equine muscle tissue-
derived, periosteal tissue-derived, bone marrow-derived, and adipose tissue-derived 
mesenchymal stem cells into subpopulations that remain viable, securing its potential for 
use in equine stem cell applications and veterinary medicine.   
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3.2. Introduction 
 The need for methods of cell sorting that are less expensive, more practical, and 
less compromising of cell viability are an important next step in both equine and human 
cellular based therapy.(1, 2)(Chapter 2) Currently fluorescence-activated cell sorting 
(FACS) is the standard for sorting populations and subpopulations of cells.(2)  The 
specific light scattering and fluorescent characteristics of each cell allow them to be 
sorted one cell at a time.  While it provides a quantitative reading of fluorescence from 
individual cells as well as physical separation of cells of particular interest, the cells are 
tagged by antibodies and fluorescent labels in preparation for FACS, thus changing their 
cell surface characteristics and impeding post-FACS assays.(3)  The vast expense and 
technical difficulty of a FACS system, the dedicated technical support to operate it, and 
the reagents required are prohibitive to many, creating a need for more readily accessible 
options in cell sorting.   
The lack of a definitive consensus on equine MSC CD marker expression is 
another complicating factor with using an immunological tagging system to sort equine 
stem cells.(4)  The available putative markers are limited and often recognize multiple 
subpopulations members of a stem cell lineage.(5)  There is a lack of reactivity between 
commercial monoclonal antibodies and epitopes on equine cells therefore phenotyping 
has been incomplete.(5) Current studies in the equine MSC field have shown positive 
expression of cell surface markers CD90 and CD44,(6, 7) and negative expression of 
CD34 and CD45.(8)  The presence of surface markers does not however, denote that 
MSCs are in a completely undifferentiated state.(3)  Sorting the MSCs with a tag-less 
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method would circumvent these CD marker issues that plague the equine MSC 
researchers.   
Mesenchymal stem cells are available for isolation from many different tissues in 
horses.(9, 10) They are sparse in numbers in post-natal tissues compared to embryonic 
tissues, creating a need for sorting methods to separate MSCs from differentiated cells in 
the tissue. Pluripotent MSC subpopulations have been identified in humans(8, 11-13) 
and rats.(14)  These subpopulations have been found to have different shapes, 
proliferation and differentiation abilities.(14, 15)  It is therefore important to be able to 
isolate the fractions of MSCs that proliferate and differentiate optimally for the 
application of interest. 
Field-flow fractionation (FFF) describes a group of bioanalytical techniques that 
have applications in the separation of bioanalytes ranging from proteins and nucleic 
acids to viruses, organelles and whole cells.(3)  Gravitational field-flow fractionation 
(GrFFF) is a type of FFF technique that relies on gravity to achieve sedimentation.(3) 
Cells differing in molar mass, size and surface antigens are driven by gravity into 
different velocity regions. The cells are then carried downstream through the channel at 
different speeds, and exit the channel after different retention times. The distribution of 
the cells into the various resulting fractions reveals the separation characteristics.(16)  
After a sedimentation step, equilibrium is reached in traditional GrFFF systems between 
the gravitational field and the hydrodynamic forces of the transport fluid stream within 
the capillary channel. Cell sedimentation in the system tends to cause cell adhesion to 
the wall of the capillary channel and cell–cell aggregation/stacking.  Due to the adherent 
nature of multipotent MSCs, non-equilibrium gravity assisted dynamic fractionation 
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(NEEGA-DF), which skips the sedimentation step, is utilized to circumvent these MSC 
tendencies and increasing cell recovery.(2, 17) 
GrFFF-based methods have been shown to be potentially useful for cellular 
applications.  The separation of neoplastic B cells from healthy B and T cells in a 
heterogeneous blood sample has been recently described.(18)  GrFFF has also been used 
to sort different human stem cells(19) and non-equilibrium GrFFF has been 
implemented to isolate, purify, and sort human MSCs from clinical specimens derived 
from different sources.(17)  Once separated from differentiated cells, the differences in 
donor tissue MSC source can be distinguished by the different elution profiles.  
Resulting fractions will have varied commitment potentials which correspond to their 
differing levels of stem cell-like activity.(3)   
 Our purpose in this study was to validate the use of non-equilibrium GrFFF as a 
sorting technique for 1) equine muscle-derived mesenchymal stem cells (MMSCs), 2) 
periosteal tissue-derived mesenchymal stem cells (PMSCs), 3) bone marrow-derived 
mesenchymal stem cells (BMSCs), and 4) adipose tissue-derived mesenchymal stem 
cells (AMSCs). 
3.3. Materials and Methods 
3.3.1. Samples   
 Six adult horses (2-5 years of age) were used for post mortem collection of bone 
marrow, periosteum, skeletal muscle, and adipose tissue. The horses were donated to the 
Atlantic Veterinary College for reasons other than this study, and were euthanized in 
accordance with University of Prince Edward Island Animal Care Committee approved 
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protocols.(Chapter 2)  All horses were first sedated with xylazine IV (1.1 mg/kg) 
(Xylamax, Bimeda, Cambridge, ON) and then euthanized with pentabarbitol sodium 
injection IV (10 ml/50 kg) (Euthanyl Forte, Bimeda, Cambridge, ON).   
3.3.2. Tissue collection and cell isolation  
Techniques were performed as described in an earlier study.(Chapter 2)  Briefly, 
immediately after euthanasia, bone marrow (Illinois bone marrow biopsy needle, 
Carefusion, San Diego, CA) was aseptically collected from the sternebrae, adipose tissue 
(24 cm
3
) from the left subcutaneous supragluteal area lateral to the tail head, muscle (9 
cm
3
) from the left semitendinosus/membranosus muscles, and periosteum (4 cm
2
) from 
the proximal medial surface of the right tibia.  The aspirate (9.5 mL) of bone marrow 
was collected from the fourth sternebrae into a 12 mL syringe that had been pre-loaded 
with 2.5 mL of 1000 IU/mL heparin (Leo Pharma Inc., Thornhill, ON).  Another sample 
was immediately drawn from the fifth sternebra in the same fashion and transported to 
the laboratory.  Cells were isolated from bone marrow via a centrifugation gradient 
technique.  The tissues collected were placed in alpha minimal essential media (αMEM, 
Invitrogen, Toronto, ON) and transported to the laboratory. Cells were isolated from fat, 
muscle, and periosteum, all by means of same enzyme digestion technique. (Chapter 2)  
3.3.3. Cell cryopreservation  
 Cells were divided into 2.5 million cell aliquots with 1.8 ml of freezing media 
(10 ml DMSO in 90 ml FBS) in cryo-vials (Corning Incorporated, Corning, NY). They 
were kept at -80
o
C for a minimum of 24 hours and then placed in a liquid nitrogen tank 
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until removed for cell culture. Viable cells were plated in T-75 (Corning Incorporated, 
Corning, NY) flasks at a cell density of 33 x 10
3 
cells/cm
2
 in standard media (SM) 
(αMEM supplemented with 10% fetal bovine serum (FBS, PAA Laboratories Inc., 
Etobicoke, ON) , L-glutamine (2 mM)( Invitrogen, Toronto, ON), 10000 U penicillin, 10 
mg streptomycin/mL (Invitrogen, Toronto, ON), and 250 μg/mL amphotericin B 
(Invitrogen, Toronto, ON)).  
3.3.4. Cell preparation   
 Cultured and expanded cells from passage 2 of each of the 4 donor tissue sources 
(muscle, periosteum, bone marrow, adipose) from 4-6 horses were used for the GrFFF.  
PMSCs and AMSCs were sorted from 4 horses, while MMSCs and BMSCs were sorted 
from 6 horses.  Cells were washed with phosphate buffered saline (PBS, Invitrogen, 
Toronto, ON) and then incubated for 30 minutes in a humidified 5% carbon dioxide and 
95% air atmosphere incubator at 37°C with 5 parts Versene (Invitrogen, Toronto, ON) to 
1 part Trypsin (Invitrogen, Toronto, ON).  The reaction was stopped with an equal 
amount of SM.  The cell suspension was spun at 377 x g for 10 minutes and the 
supernatant removed.  The pellet was vortexed and resuspended in 3 ml mobile phase 
solution (1g BSA, Bovine serum albumin, Fischer Scientific, Fair Lawn, NJ) in 1L PBS 
made with ultra pure water and 5000 U penicillin, 5 mg streptomycin/mL).  Aliquots of 
800 x 10
3
 cells from each sample were seeded into 6 Eppendorf vials, spun down at 377 
x g for 7 minutes, and the supernatant was removed.  Fifty microlitres of mobile phase 
solution was added to each Eppendorf vial and cells were resuspended.   
3.3.5. GrFFF System  
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GrFFF system was purchased from byFlow s.r.l. (byFlow s.r.l, Bologna, Italy) 
and assembled and operated as per manufacturer’s instructions.  Sterilization of the 
fractionation system and the 100-μL HPLC syringe (Hamilton, Reno, NV) to be used for 
sample loading was performed at the beginning of each working day as previously 
described and schematized.(2,19)  Each aliquot of 800 x 10
3
 cells was then individually 
injected into the GrFFF system(2,17) and sorted into 6 fractions by changing the 
collection tube every 5 minutes.  This timing was based on human MSC sorting work 
done with the GrFFF system(2) and validation work done in our laboratory that graphed 
the absorbency readings at different intervals and adjusted the collection times until 
fraction absorbencies were consistently different from one group to the next.  The 
absorbencies (optical densitiy, OD) of the six fractions were then characterized by 
spectrophotometric analysis (LKB Biochrom Ultrospec II 4050 UV/Vis 
Spectrophotometer, Biochrom, Holliston, MA) at a wavelength of 600 nm.  The 6 
fractions from each of the 6 aliquots were combined to provide pooled fractions that 
were numerically assessed by hemocytometric anaylsis and seeded at equal 
concentrations into assays as diagramed in Figure 3.1.   
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Figure 3.1 Diagram of steps of GrFFF cell sorting study design.  Six horses had four 
tissues collected (bone marrow, adipose, muscle and periosteum) and MSCs cultured 
from each tissue. Each aliquot of 800 x10
3
 cells was then individually sorted by the 
GrFFF system into 6 fractions.  The absorbencies (OD) of each fraction were 
determined.  The sorting process was done on 6 different aliquots and then resulting 
fractions were combined to provide pooled fractions for further culture. 
3.3.6. Characterization of sorted MSCs 
Sorted cells from each tissue source were seeded at a density of 1,300 cells/cm
2  
into 30 mm tissue culture dishes (Corning Incorporated, Corning, NY) and 
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supplemented with and maintained for one week in standard medium after which 
adherence to the flask and spindle shaped morphology was confirmed using direct 
microscopic analysis at 10x.   
3.3.7. Cell differentiation  
Cells from each tissue source from each of 3 individuals were induced, as 
described below, to differentiate into the following three lineages for evaluation:  1.) 
adipocyte, 2.) chondrocyte, and 3.) osteoblast.  Each of the 3 lineages was cultured in 
parallel with one in standard media as previously described.(Chapter 2)  Light 
microscopy (Axiovert 40 CFL, Carl Zeiss Canada Ltd., Toronto, ON) digital images 
(Power shot G5, Canon, Mississauga, ON) were taken on day 7 at 10x to assess the 
different morphologies.  Histochemistry and morphology was used to confirm 
differentiation into the 3 lineages as described below. 
3.3.8. Adipogenic differentiation  
Cells were seeded at a density of 1,300 cells/cm
2 
into 35 mm wells.  Cells were 
first cultured for 3 days in standard medium.  Thereafter, the cells were exposed to an 
adipogenic induction medium (AM) (DMEM/F12 (Invitrogen, Toronto, ON), 3% FBS, 
10000 U penicillin and 10 mg streptomycin/ml, 250 μg/ml amphotericin B, 33 μmol/L 
biotin (Sigma, Oakville, ON), 17 μmol/L pantothenate (Sigma, Oakville, ON), 1 μmol/L 
insulin (Sigma, Oakville, ON), 1 μmol/L dexamethasone (Sigma, Oakville, ON), 
0.5 mmol/L isobutylmethylxanthine (IBMX, Sigma, Oakville, ON), 5 μmol/L 
rosiglitazone (Toronto Research Chemicals, Toronto, ON) and 5% rabbit serum 
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(Invitrogen, Toronto, ON)) for 2 days.  Thereafter, the same medium without the IBMX 
and the rosiglitazone was used to maintain the adipocyte cell culture until day 7 when 
the cells were fixed for 20 minutes in 10% neutral buffered formalin (Fisher Scientific, 
Nepean, ON) at room temperature and stained for neutral lipid accumulation with Oil 
Red O indicating adipogenic differentiation. (20) 
3.3.9. Chondrogenic differentiation   
Cells were seeded at a density of 1,300 cells/cm
2
 into 35 mm wells and 
supplemented with a chondrogenic differentiation medium (CM) (Hams 12 (Sigma, 
Oakville, ON), dexamethasone (10-7 M), ITS+1(Sigma, Oakville, ON) (culture 
supplement containing bovine insulin, transferrin, selenous acid, linoleic acid, and BSA) 
5% FCS, 10000U penicillin and 10 mg streptomycin/mL, 250 μg/mL amphotericin B, 50 
µg/mL ascorbic acid (Sigma, Oakville, ON), 1 ng/mL recombinant human transforming  
growth factor-beta 1(rhTGF-beta1,Millipore Temecula,CA).  Cultures were maintained 
for 7 days and then fixed for 20 minutes in 10% neutral buffered formalin at room 
temperature.  Cultures were then stained with Alcian blue pH 1.0 for the detection of 
sulfated proteoglycans to confirm chondrogenic differentiation.  
3.3.10. Osteoblastic differentiation  
Cells were seeded at a density of 1,300 cells/cm
2 
into 35 mm wells.  Cells were 
supplemented with an osteogenic induction medium (OM) (α-MEM, 5% FCS, 10000 U 
penicillin and 10 mg streptomycin/mL, 250 μg/ml amphotericin B, 50 µg/mL ascorbic 
acid, dexamethazone 10
-8
, and 10 mM β-glycerophosphate (Sigma, Oakville, ON)).  
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Cultures were maintained for 7 days and then fixed for 20 minutes in 10% neutral 
buffered formalin at room temperature.  Cultures were then stained for calcium with von 
Kossa stain(21) and with the substrate naphthol AS MX-PO4 and Red Violet LB salt for 
alkaline phosphatase(22) to confirm mineralization and osteoblastic differentiation. 
3.3.11. Statistical analysis   
Comparison of fraction absorbencies was performed using a paired T-test with horse as 
the experimental unit.  Significance was set at values of P < 0.05. 
3.4. Results 
3.4.1. Spectrophotometric analysis of each fraction 
MMSCs, PMSCs, BMSCs, and AMSCs were sorted by GrFFF into six fractions, 
and this was repeated six times. The fraction contents were compared by 
spectrophotometric absorbance (Figure 3.2a-d) as an objective comparison of cell 
number and size.  Fractions 1 and 5 OD values were very close to zero (readings in 
thousandths) due to the cells’ small size/number and fraction 6 was zero due to complete 
lack of cells.  Absorbencies of fraction 2 and 3 compared to fractions 1, 4, 5, and 6 for 
each tissue revealed significant difference (P<0.5).  In general, fractions with higher 
absorbencies also had higher cell counts and fractions with lower absorbencies had 
lower cell counts. 
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Figure 3.2a Graph of absorbance (OD) vs. fraction for 6 horses (bold numbered panels) 
and replicates 1-6 (lines) of sorted cells derived from muscle tissue.  Note the 
consistency in absorbency between fraction replicates. Fraction 1 (●), fraction 2 (■), 
fraction 3 (♦), fraction 4 (▲), fraction 5 (►), fraction 6 (◄).  
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Figure 2b Graph of absorbance (OD) vs. fraction for 4 horses (bold numbered panels) 
and replicates 1-6 (lines) of sorted cells derived from periosteal tissue.  Note the 
consistency in absorbency between fraction replicates.  Fraction 1 (●), fraction 2 (■), 
fraction 3 (♦), fraction 4 (▲), fraction 5 (►), fraction 6 (◄). 
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Figure 2c Graph of absorbance (OD) vs. fraction for 6 horses (bold numbered panels) 
and replicates (1-6) of sorted cells derived from bone marrow.  Note the consistency in 
absorbency between fraction replicates.  Fraction 1 (●), fraction 2 (■), fraction 3 (♦), 
fraction 4 (▲), fraction 5 (►), fraction 6 (◄). 
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Figure 2d Graph of absorbance (OD) vs. fraction for 4 horses (bold numbered panels) 
and replicates 1-6 (lines) of sorted cells derived from adipose tissue.  Note the 
consistency in absorbency between fraction replicates.  Fraction 1 (●), fraction 2 (■), 
fraction 3 (♦), fraction 4 (▲), fraction 5 (►), fraction 6 (◄). 
3.4.2. Microscopic analysis of each fraction 
 Each MSC type (MMSCs, PMSCs, BMSCs, and AMSCs) from each horse had 
cells in fractions 1-5, but none in fraction 6.  Cells from all cell sources and fractions 
adhered to the plastic culture substrate used.  The cell recovery from GrFFF sorting 
system was poor overall and ranged from 28-73%.  This range was attributed to inter-
horse variation.  The highest number of cells was found in fractions 2, 3, and 4 in all 
tissues. The morphology of cells in fraction 1 was more cuboidal while cells in fractions 
2-5 were more classic fibroblastic spindle shapes indicating that different subpopulations 
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were indeed separated from one another (Figure 3.3).  MMSCs, PMSCs, BMSCs, and 
AMSCs were sorted by non-equilibrium GrFFF while maintaining sterility and viability.  
 
Figure 3.3  Representative photomicrographs of differing morphology between fractions 
of MSCs cultured from GrFFF sorted equine muscle.  Note that the morphology of cells 
in fraction 1 was more cuboidal in comparison to fractions 2-5 that were more classic 
fibroblastic spindle shapes.  All are unstained.  Scale bar 200µm. 
3.4.3. Trilineage differentiation 
 Cells from fractions 1-5 from each tissue were able to undergo tri-lineage 
differentiation as seen in the representative photomicrographs in Figure 3.4. Cells 
cultured in adipogenic differentiation medium for 4 days had positive results for oil red 
O staining of lipid droplets. Cells cultured in standard medium did not develop lipid 
droplets and lacked staining with oil red O. MSCs cultured in chondrogenic 
differentiation medium for 7 days stained positively for glycosaminoglycans with Alcian 
blue. Cells cultured in standard medium lacked Alcian blue stain uptake. Cells cultured 
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in osteogenic differentiation medium for 7 to 10 days formed bone nodules based on 
positive results of alkaline phosphatase and calcium specific stains. Cells cultured in 
standard medium did not develop nodules and lacked staining for alkaline phosphatase 
and calcium. 
 
Figure 3.4 Representative photomicrographs of GrFFF sorted MSCs (fractions 1-5 from 
each tissue) after tri-lineage differentiation and histochemical staining. Osteogenic 
medium is stained with von Kossa stain (A), adipogenic medium  is stained with oil red 
O (B), chondrogenic medium is stained with Alcian blue (C), and standard medium is 
unstained (D).  Scale bar is 200µm. 
3.5. Discussion and Conclusions 
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 This is the first study to validate the use of non-equilibrium GrFFF as a sorting 
method for equine derived MMSCs, PMSCs, BMSCs, and AMSCs.  The cells from each 
source were driven by gravity into different velocity regions and successfully sorted into 
fractions revealing that they possess differences in molar mass, size or surface antigens. 
The fractions with higher absorbencies also had higher cell counts, while those with 
lower absorbencies had lower cell counts.  Cell size likely also plays a part in the 
absorbency measurements as larger cells travel more quickly through the chamber than 
do smaller cells.(2) However, in this study we measured cell number and did not 
measure cell size.   
MMSCs, PMSCs, BMSCs, and AMSCs used for non-equilibrium GrFFF sorting 
in this study were previously characterized by morphology, adherence to polystyrene 
plastic (tissue culture substrate), tri-lineage differentiation, and stem cell surface marker 
detection by immunofluorescence and flow cytometric analysis.(Chapter 2)  Although 
populations of cells from each tissue had a high percentage of purity based on the flow 
cytometry results from this previous work, it became obvious in the present study, that 
several subpopulations were present in each sample. The populations sorted into 
fractions that each had different absorbencies, and were therefore concluded to be 
differing subpopulations.  These subpopulations were found to have trilineage 
differentiation capabilities, thus have not been altered by the sorting process.  Evidence 
from this study indicates that cell sorting by properties other than cell surface markers is 
essential when the phenotype has not been completely elucidated.  
This study aimed at validation of the non-equilibrium GrFFF technique for use 
with equine MSCs which has not to the author’s knowledge been published before.  
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Other studies using other sorting techniques, other MSC sources, and other species have 
been reported.  One group used equine MCSs derived from intervascular and 
perivascular umbilical cord matrix and sorted them by a size-sieving method.(23) They 
were successful in sorting the cells into two homogenous sub-populations and found the 
large intervascular cells and small perivascular cells to have faster proliferation rates 
than unsorted controls.  The sub-populations however, had similar marker expression 
and differentiation potential to one another, suggesting that further sorting by cell 
surface characteristics may have been possible. Another group used the non-equilibrium 
GrFFF technique with human MSCs to successfully obtain a homogeneous population of 
MSCs from a heterogenous one, to sort MSCs with dissimilar differentiation potentials, 
and to distinguish MSCs from different sources that had differing cell surface 
markers.(17)  Roda et. al. showed the cell surface differences definitively using FACS 
analysis which this research will employ in future investigations of the homogeneous 
subpopulations that were isolated from a heterogeneous equine MSC population. 
Many aspects of the non-equilibrium GrFFF technique make it ideal for use in 
cell culture.  Non-equilibrium GrFFF allows for the improvement of MSC isolation time 
by clearing other cells and contaminates from the sample in an early passage.(24, 25) 
Conventionally, this is achieved by adherence and detachment cycles implemented over 
several passages during cell culture.  The shortening of this clean-up phase with a 
technique such as GrFFF is of great use in clinical application of stem cell therapy as it 
shortens the return time on samples received for injured patients.(2, 26) 
The GrFFF technology is similar to fluorescence activated cell sorting (FACS) in 
that it is a system to sort subpopulations of cells but it is superior in several aspects.  The 
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non-equilibrium GrFFF is a tag-less system of stem cell sorting that will avoid 
augmentation of the MSCs.(2)  The GrFFF sorting system is also very economical as it 
can be assembled and maintained in the laboratory from inexpensive instruments and 
reagents owned by most biotechnology laboratories or purchased for a fraction of the 
cost of a FACS machine.  The GrFFF system is also far less technically difficult to 
operate than the FACS system.  Perhaps most importantly, GrFFF allows for the MSCs 
to be maintained under sterile conditions also allowing for further culture, expansion, 
assays, and use in cell based therapies after fractionation.(3)  In the current study it was 
also confirmed that MMSCs, PMSCs, BMSCs, and AMSCs can be sorted by non-
equilibrium GrFFF while maintaining viability for further assays.  
The main limitation to this system is the low number of cells that can be 
fractionated per run.  Another study discovered a polar hydrophobic environment on the 
PVC material used in the GrFFF system which explains the low recovery of biological 
sample.  A coating was placed on the polyvinylchloride which improved the sample 
returns.(27)  As we were validating the system for use with equine MSC for the first 
time, we chose to use the system in its simplest form.  We increased sorting throughput 
by pooling fractions collected at the same retention times from repeated runs.  After 
validation of a single system with human lymphocytes, others have set up two GrFFF 
channels in parallel to increase sorting throughput.(19)  
In equine regenerative medicine, identification of the optimum source of MSCs, 
or other progenitor cells, for each application has been the focus of much 
evaluation.(Chapter2) (9, 10, 28, 29) This research points out that the variation of MSCs 
within each source must also be taken into consideration.  Techniques for sorting and 
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enrichment of MSCs may be the key to isolation of the equine MSC phenotypes.  To this 
end, future goals include using non-equilibrium GrFFF for MSC purification and 
fractionation into subpopulations to be evaluated for CD markers using flow cytometry.  
Once the phenotype is elucidated, comparative assays between the fractions will 
determine the optimum source and CD markers of MSCs for the intended application. 
With this information the GrFFF system will be employed to isolate the subpopulation 
of interest allowing for culture and expansion of an ultrapure population.  
In summary, the ability to affordably and effectively sort equine MSCs with non-
equilibrium GrFFF now broadens the choices available to clinicians using MSCs in cell 
based therapies. 
3.6. References 
1. Triffitt JT. The stem cell of the osteoblast. San Diego, CA: Academic Press, Inc.; 
1996;1:39-50.  
2. Roda B, Lanzoni G, Alviano F, et al. A novel stem cell tag-less sorting method. Stem 
Cell Rev. 2009;5:420-427. doi:10.1007/s12015-009-9088-7.  
3. Roda B, Zattoni A, Reschiglian P, et al. Field-flow fractionation in bioanalysis: A 
review of recent trends. Anal Chim Acta. 2009;635:132-143. 
doi:10.1016/j.aca.2009.01.015.  
4. De Schauwer C, Meyer E, Van de Walle GR, Van Soom A. Markers of stemness in 
equine mesenchymal stem cells: A plea for uniformity. Theriogenology. 2011;75:1431-
1443. doi:10.1016/j.theriogenology.2010.11.008.  
100 
 
5. Taylor SE, Smith RK, Clegg PD. Mesenchymal stem cell therapy in equine 
musculoskeletal disease: Scientific fact or clinical fiction? Equine Vet J. 2007;39:172-
180.  
6. Radcliffe CH, Flaminio MJ, Fortier LA. Temporal analysis of equine bone marrow 
aspirate during establishment of putative mesenchymal progenitor cell populations. Stem 
Cells Dev. 2010;19:269-282. doi:10.1089/scd.2009.0091.  
7. de Mattos Carvalho A, Alves AL, Golim MA, et al. Isolation and immunophenotypic 
characterization of mesenchymal stem cells derived from equine species adipose tissue. 
Vet Immunol Immunopathol. 2009;132(2-4):303-6. doi:10.1016/j.vetimm.2009.06.014.  
8. Stillwell C, Wang F, Xiang B, et al. Adipose tissue houses different subtypes of stem 
cells. Can J Physiol Pharmacol. 2012;90:1295-1301. doi:10.1139/y2012-094; 
10.1139/y2012-094.  
9. Toupadakis CA, Wong A, Genetos DC, et al. Comparison of the osteogenic potential 
of equine mesenchymal stem cells from bone marrow, adipose tissue, umbilical cord 
blood, and umbilical cord tissue. Am J Vet Res. 2010;71:1237-1245. 
doi:10.2460/ajvr.71.10.1237.  
10. Iacono E, Brunori L, Pirrone A, et al. Isolation, characterization and differentiation 
of mesenchymal stem cells from amniotic fluid, umbilical cord blood and wharton's jelly 
in the horse. Reproduction. 2012;143:455-468. doi:10.1530/REP-10-0408; 
10.1530/REP-10-0408.  
11. Ranera B, Lyahyai J, Romero A, et al. Immunophenotype and gene expression 
profiles of cell surface markers of mesenchymal stem cells derived from equine bone 
101 
 
marrow and adipose tissue. Vet Immunol Immunopathol. 2011;144:147-154. 
doi:10.1016/j.vetimm.2011.06.033.  
12. Aquino JB, Bolontrade MF, Garcia MG, Podhajcer OL, Mazzolini G. Mesenchymal 
stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular 
carcinoma. Gene Ther. 2010;17:692-708. doi:10.1038/gt.2010.10.  
13. Sun JS, Wu SY, Lin FH. The role of muscle-derived stem cells in bone tissue 
engineering. Biomaterials. 2005;26:3953-3960. doi:10.1016/j.biomaterials.2004.10.016.  
14. Zhang L, Chan C. Isolation and enrichment of rat mesenchymal stem cells (MSCs) 
and separation of single-colony derived MSCs. J Vis Exp. 2010;(37). pii: 1852. 
doi:10.3791/1852. doi:10.3791/1852; 10.3791/1852.  
15. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem 
cells derived from adult marrow. Nature. 2002;418:41-49. doi:10.1038/nature00870.  
16. Reschiglian P, Zattoni A, Roda B, Michelini E, Roda A. Field-flow fractionation and 
biotechnology. Trends Biotechnol. 2005;23:475-483. doi:10.1016/j.tibtech.2005.07.008.  
17. Roda B, Reschiglian P, Zattoni A, et al. A tag-less method of sorting stem cells from 
clinical specimens and separating mesenchymal from epithelial progenitor cells. 
Cytometry B Clin Cytom. 2009;76B:285-290. doi:10.1002/cyto.b.20472.  
18. Roda B, Reschiglian P, Zattoni A, et al. Human lymphocyte sorting by gravitational 
field-flow fractionation. Anal Bioanal Chem. 2008;392:137-145. doi:10.1007/s00216-
008-2271-x.  
19. Roda B, Reschiglian P, Alviano F, et al. Gravitational field-flow fractionation of 
human hemopoietic stem cells. J Chromatogr A. 2009;1216:9081-9087. 
doi:10.1016/j.chroma.2009.07.024.  
102 
 
20. Vidal MA, Kilroy GE, Lopez MJ, Johnson JR, Moore RM, Gimble JM. 
Characterization of equine adipose tissue-derived stromal cells: Adipogenic and 
osteogenic capacity and comparison with bone marrow-derived mesenchymal stromal 
cells. Vet Surg. 2007;36:613-622. doi:10.1111/j.1532-950X.2007.00313.x.  
21. Bhargava U, Bar-Lev M, Bellows CG, Aubin JE. Ultrastructural analysis of bone 
nodules formed in vitro by isolated fetal rat calvaria cells. Bone. 1988;9:155-163.  
22. Burstone MS. Histochemical observations on enzymatic processes in bones and 
teeth. Ann N Y Acad Sci. 1960;85:431-444.  
23. Corradetti B, Lange-Consiglio A, Barucca M, Cremonesi F, Bizzaro D. Size-sieved 
subpopulations of mesenchymal stem cells from intervascular and perivascular equine 
umbilical cord matrix. Cell Prolif. 2011;44:330-342. doi:10.1111/j.1365-
2184.2011.00759.x; 10.1111/j.1365-2184.2011.00759.x.  
24. Lautrette C, Cardot PJ, Vermot-Desroches C, Wijdenes J, Jauberteau MO, Battu S. 
Sedimentation field flow fractionation purification of immature neural cells from a 
human tumor neuroblastoma cell line. J Chromatogr B Analyt Technol Biomed Life Sci. 
2003;791:149-160.  
25. Urbankova E, Vacek A, Chmelik J. Micropreparation of hemopoietic stem cells from 
the mouse bone marrow suspension by gravitational field-flow fractionation. J 
Chromatogr B Biomed Appl. 1996;687:449-452.  
26. Owens SD, Burges J, Johns JL, et al. Processing of equine bone marrow using the 
automated MarrowXpress system: RBC depletion, volume reduction, and mononuclear 
cell recovery. Vet Clin Pathol. 2011;40:444-449. doi:10.1111/j.1939-
165X.2011.00368.x; 10.1111/j.1939-165X.2011.00368.x.  
103 
 
27. Roda B, Cioffi N, Ditaranto N, et al. Biocompatible channels for field-flow 
fractionation of biological samples: Correlation between surface composition and 
operating performance. Anal Bioanal Chem. 2005;381:639-646. doi:10.1007/s00216-
004-2860-2.  
28. Stewart AA, Barrett JG, Byron CR, et al. Comparison of equine tendon-, muscle-, 
and bone marrow-derived cells cultured on tendon matrix. Am J Vet Res. 2009;70:750-
757. doi:10.2460/ajvr.70.6.750.  
29. McDuffee LA, Anderson GI. In vitro comparison of equine cancellous bone graft 
donor sites and tibial periosteum as sources of viable osteoprogenitors. Vet Surg. 
2003;32:455-463. doi:10.1053/jvet.2003.50060.  
 
 1. Radtke CL, Nino-Fong R, Rodriguez-Lecompte JC, Esparza Gonzalez B, Stryhn H, 
McDuffee LA. Osteogenic potential of sorted equine mesenchymal stem cell 
subpopulations. Can J Vet Res. Accepted March 2014.  
4. OSTEOGENIC POTENTIAL OF SORTED EQUINE MESENCHYMAL STEM 
CELL SUBPOPULATIONS
1
  
4.1. Abstract 
 The objective of this study was to use non-equilibrium gravitational field-flow 
fractionation (GrFFF), an immunotag-less method of sorting mesenchymal stem cells 
(MSCs) into subpopulations, to sort equine muscle tissue-derived (MMSC) and bone 
marrow-derived mesenchymal stem cells (BMSC) into subpopulations and then to 
perform assays allowing comparison of their osteogenic capabilities.  Cells were isolated 
from left semitendinosus muscle tissue, and from bone marrow aspirates of the fourth 
and fifth sternebrae from one young, adult horse.  Aliquots of 800 x10
3
 MSCs from each 
tissue source were sorted into 5 fractions using non-equilibrium GrFFF (GrFFF 
proprietary system).  Equine MMSCs and BMSCs were consistently sorted into 5 
fractions that remained viable for use in further osteogenic assays.  Pooled fractions 
were cultured and expanded for use in assays including: flow cytometry; 
Histochemistry; bone nodule assays; and real time qPCR to identify gene expression of 
osteocalcin, RUNX2, and osterix.  Statistical analysis confirmed strongly significant 
upregulation of osteocalcin, RUNX2, and osterix for the BMSC fraction 4 with 
P<0.00001.  Flow cytometry revealed different cell size and granularity for BMSC 
fraction 4 and MMSC fraction 2 when compared with unsorted controls (whole 
population) and other fractions.  Histochemisty and bone nodule assays revealed positive 
staining nodules but no significant differences between tissue sources or fractions.  
Subpopulations of MSCs exist and have different osteogenic capacities within equine 
muscle and bone marrow derived sources; therefore, it is important to consider these 
differences when using equine stem cell therapy to induce bone healing in veterinary 
medicine. 
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4.2. Introduction 
 Expedited fracture healing in horses is needed due to the inherent risks of 
contralateral limb laminitis, cyclic loading and fatigue failure of implants,(1) and non-
unions due to disturbed blood supply to the injured bone.(2)  The most common method 
to accelerate bone healing in horses is the use of an autogenous, cancellous bone 
graft.(3)  Bone tissue engineering methods, including the use of mesenchymal stem cells 
(MSCs) to enhance bone healing, have been evaluated in research studies in many 
species.(4-7) Ectopic bone formation has been verified for MSCs injected 
subcutaneously in dogs,(8) and porcine maxillary sinus defects have shown increased 
boney healing when filled with MSCs.(9) The injection of MSCs into non-union 
fractures of humans has proven to be safe and effective for healing deficits in bone.(10)  
The injection of MSCs into the distraction gap of rats has been shown to have 
encouraging results in preventing a non-union.(11)  Other in vitro studies,(12, 13) have 
demonstrated the potential for the use of  MSC-based treatments in equine 
musculoskeletal injuries.  While MSC therapies show promise, they are in great need of 
standardization and refinement prior to clinical use to increase their effectiveness and 
success.   
Part of that refinement can be addressed by making efforts to use the purest 
cultures of stem cells that are optimal at healing the tissue of interest.  It is well known 
that MSCs derived from a single source are made up of a heterogeneous population.(14, 
15)  Subpopulations of MSCs are documented within many tissue types and species(16) 
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including mouse bone (17), blood (18) and  muscle,(19) rat bone marrow (20) and 
calvarial bone (21), human heart (22) and adipose (23), equine adipose (24)(Chapter 2), 
umbilical cord (25), muscle, periosteum, and bone marrow (Chapter 2).  These cell 
subpopulations have been found to have different shapes, proliferation and 
differentiation abilities. (20, 26)  It is therefore important to be able to isolate the 
fraction of MSCs that proliferates and differentiates optimally for the application of 
interest.  
Identification of the source and subpopulation of MSCs with the best osteogenic 
potential may prove vital for moving basic science research toward clinical cell-based 
treatments to promote bone healing.(27) The sorting of cells into their respective 
subpopulations is traditionally conducted using fluorescence-activated cell sorting 
(FACS).(28) Due to the high cost, complicated technique, reliance on clearly elucidated 
cell surface markers,(29) and the cell function altering nature of the FACS process,(30) a 
more economic and less harsh method is required.  
Field-flow fractionation (FFF) encompass a group of bioanalytical techniques 
that can be used in the separation of bioanalytes ranging from proteins and nucleic acids 
to viruses, organelles and whole cells.(30) Non-equilibrium gravitational field-flow 
fractionation (GrFFF) is a flow through type of FFF technique that relies on gravity to 
sort MSCs(31) based on differences in molar mass, size and surface antigens.  The cells 
settle into different velocity regions of the fluid filled channel, are carried downstream at 
different speeds, and exit the channel after different retention times. The division of the 
cells into the various resulting fractions reveals the separation characteristics.(32)   
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GrFFF-based methods have been shown to be useful for cellular applications.  
GrFFF has been used to sort human stem cells(33) and non-equilibrium GrFFF has been 
used to isolate, purify, and sort human MSCs derived from different sources.  The 
distinctions between donor tissue MSC sources may be distinguished by the different 
elution profiles.  Resulting fractions will have an array of commitment potentials that 
correlate with their differing degrees of stem cell-like potential.(30)  
Previous work in our lab has validated the use of a non-equilibrium gravitational 
field-flow fractionation (GrFFF) MSC sorting system for use with equine 
MSCs,(Chapter 3) and has shown that muscle and bone marrow may be preferred tissue 
sources for promotion of bone healing based on osteogenic capacity when compared to 
periosteum and adipose tissue.(Chapter 2) Based on these findings, we employed the use 
of the non-equilibrium GrFFF system to sort cells into their respective subpopulations so 
that the osteogenic capabilities of cells in each subpopulation could be further studied.  
We hypothesized that equine muscle and bone marrow derived MSCs would 
consist of subpopulations that would not have differing osteogenic capabilities.  The 
purpose of the study reported here was to compare the osteogenic capacities of unsorted 
equine muscle-derived mesenchymal stem cells (MMSCs) and bone marrow-derived 
mesenchymal stem cells (BMSCs), with subpopulations of MMSCs and BMSCs sorted 
by a non-equilibrium GrFFF system. 
4.3. Materials and Methods 
4.3.1. Samples   
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 A two year old Standardbred gelding was used for post mortem collection of 
bone marrow, and skeletal muscle. The horse was donated to the Atlantic Veterinary 
College for reasons other than this study, and was euthanized in accordance with 
University of Prince Edward Island Animal Care Committee approved 
protocols.(Chapter 2)  The horse was first sedated with xylazine IV (1.1 mg/kg) 
(Xylamax, Bimeda, Cambridge, ON) and then euthanized with pentabarbitol sodium 
administered IV (10 ml/50 kg) (Euthanyl Forte, Bimeda, Cambridge, ON).   
Tissue collection and cell isolation techniques were performed as described in 
chapter 3.  Briefly, immediately after euthanasia, bone marrow was aseptically collected 
from the sternebrae using a bone marrow biopsy needle (Illinois bone marrow biopsy 
needle, Carefusion, San Diego, CA) and muscle (9 cm
3
) was aseptically collected from 
the left semitendinosus/membranosus muscle.  The aspirate (9.5 mL) of bone marrow 
was collected from the fourth sternebrae into a 12 mL syringe that had been pre-loaded 
with 2.5 mL of 1000 IU/mL heparin (Leo Pharma Inc., Thornhill, ON).  Another sample 
was immediately drawn from the fifth sternebra in the same fashion and transported to 
the laboratory.  Cells were isolated from bone marrow via a centrifugation gradient 
technique.(Chapter 2)  The tissues collected were placed in alpha minimal essential 
media (αMEM, Invitrogen, Toronto, ON) and transported to the laboratory. Cells were 
isolated from muscle by means of an enzyme digestion technique.(Chapter 2) 
4.3.2. Cell cryopreservation  
 Cells were divided into 2.5 million cell aliquots with 1.8 ml of freezing media 
(10 ml DMSO in 90 ml fetal bovine serum (FBS)) in cryo-vials (Corning Incorporated, 
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Corning, NY). They were kept at -80
o
C for a minimum of 24 hours and then placed in a 
liquid nitrogen tank until removed for cell culture.(Chapter 2, Chapter 3) (25, 34)Viable 
cells were plated in T-75 (Corning Incorporated, Corning, NY) flasks at a cell density of 
33 x 10
3 
cells/cm
2
 in standard media (SM) (αMEM supplemented with 10% FBS) (PAA 
Laboratories Inc., Etobicoke, ON) , L-glutamine (2 mM)( Invitrogen, Toronto, ON), 
10000 U penicillin, 10 mg streptomycin/mL (Invitrogen, Toronto, ON), and 250 μg/mL 
amphotericin B (Invitrogen, Toronto, ON)).  
4.3.3. Cell preparation 
Cultured and expanded cells from passage 2 of each of the 2 donor tissue sources 
(muscle, bone marrow) were used for the GrFFF.  Cells were washed with phosphate 
buffered saline (PBS) (Invitrogen, Toronto, ON) and then incubated for 30 minutes in a 
humidified 5% carbon dioxide and 95% air atmosphere incubator at 37°C with 5 parts 
Versene (Invitrogen, Toronto, ON) to 1 part trypsin (Invitrogen, Toronto, ON).  The 
reaction was stopped with an equal amount of standard media.  The cell suspension was 
spun at 377 x g for 10 minutes and the supernatant removed.  The pellet was vortexed 
and resuspended in 3 mL mobile phase solution; 1g BSA (Bovine serum albumin, 
Fischer Scientific, Fair Lawn, NJ) in 1L PBS made with ultra pure water and 5000 U 
penicillin, 5 mg streptomycin/mL).  Six aliquots of 800 x 10
3
 cells from each tissue 
sample source were seeded into individual Eppendorf vials, spun down at 377 x g for 7 
minutes, and the supernatant was removed.  Fifty microlitres of mobile phase solution 
was added to each Eppendorf vial and cells were resuspended.   
4.3.4. GrFFF system  
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GrFFF system (byFlow s.r.l, Bologna, Italy) was assembled and operated as per 
manufacturer’s instructions.  Sterilization of the fractionation system and the 100 μL 
HPLC syringe (Hamilton, Reno, NV) to be used for sample loading was performed at 
the beginning of each working day as previously described.(28, 33)  Each aliquot of 800 
x 10
3
 cells was then individually injected into the GrFFF system(28, 31) and sorted into 
5 fractions by changing the collection tube every 5 minutes.  This timing was based on 
human MSC sorting work done with the GrFFF system (28) and validation work done in 
our laboratory that graphed the absorbency readings at different intervals and adjusted 
the collection times until fraction absorbencies (optical density), characterized by 
spectrophotometric analysis (LKB Biochrom Ultrospec II 4050 UV/Vis 
Spectrophotometer, Biochrom, Holliston, MA) at a wavelength of 600 nm, were 
consistently different among groups as shown in chapter 3.  For each tissue sample 
source, the 5 fractions sorted from each of the 6 aliquots, and one unsorted group of the 
whole population, were combined to provide pooled fractions that were assessed by 
hemocytometric anaylsis for cell count.  Pooled fractions were plated in T-75 (Corning 
Incorporated, Corning, NY) flasks at a cell density of 33 x 10
3 
cells/cm
2
 in standard 
media. Each fraction was expanded until there were four T-75 flasks at 80% confluence, 
about 22.4 million cells, which was enough cells for consistent seeding in osteogenic 
assays as described below. 
4.3.5. Osteoblastic cell differentiation and nodule quantification 
Sorted cells and unsorted cells, from each tissue source, were seeded at a density 
of 1,300 cells/cm
2  
into 30 mm dishes (Corning Incorporated, Corning, NY) and induced 
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to differentiate in parallel with one control in standard media as previously described in 
chapter 2.  Cells were supplemented with an osteogenic induction medium (OM) (α-
MEM, 5% FBS, 10000 U penicillin and 10 mg streptomycin/mL, 250 μg/ml 
amphotericin B, 50 µg/mL ascorbic acid, dexamethazone 10
-8
M, and 10 mM β-
glycerophosphate (Sigma, Oakville, ON)).  Cultures were maintained for 7 days and 
then fixed for 20 minutes in 10% neutral buffered formalin at room 
temperature.(Chapter 2) Cultures were then stained for calcium with von Kossa stain(35) 
and with the substrate naphthol AS MX-PO4 and Red Violet LB salt for alkaline 
phosphatase(36) to confirm mineralization of bone nodules and osteoblastic 
differentiation.  Light microscopy (Axiovert 40 CFL, Carl Zeiss Canada Ltd., Toronto, 
ON) digital images (Power shot G5, Canon, Mississauga, ON) were taken at 10x on day 
7 to count the number of bone nodules formed per 20 randomized fields. Quantification 
of average area, average perimeter, and average intensity were then measured with 
computer software (Sigma Scan Pro 5, Systat Software, Inc.,San Jose, CA). 
Comparisons were made between tissue source, fractions, and unsorted controls. 
4.3.6. Flow cytometric analysis of MSC surface markers  
Cultured and expanded cells from the second passage of each of the 5 fractions 
and the one unsorted control from both bone marrow and muscle tissue were used for the 
flow cytometric analysis. The amount of antibody used in cell labeling section below, 
was optimized with a cytometer (FACSAria flow cytometer, BD Biosciences, 
Mississauga, ON). 
4.3.6.1. Cell preparation 
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Cells were washed with PBS solution and then incubated for 15 minutes in a 
humidified incubator at 5% CO2 and 95% air at 37°C with a mixture of versene 
(Invitrogen, Toronto, ON) and trypsin (5:1). (Chapter 2) The reaction was stopped with 
an equal amount of standard medium. The cell suspension was centrifuged (377 X g for 
10 minutes), and the pellet then was resuspended and washed in ice-cold 1% BSA in 
PBS solution. The cell suspension was again centrifuged (377 X g for 10 minutes), and 
the resulting pellet was resuspended in ice-cold 1% BSA in PBS solution, stained with 
trypan blue to determine viability, and counted for flow cytometric analysis. 
4.3.6.2. Cell labeling 
One million cells per sample were labeled. For each of the 5 fractions and one 
unsorted control group, one sample was unstained and served as a negative control 
sample. Successive samples were labeled with previously validated (29, 37, 38) 
antibodies (CD45, CD44, CD90, CD34, CD 29, CD14, CD79, and MHCII respectively) 
that were shown to cross react with equine cells as there are no equine specific 
antibodies available. The isotypes of these antibodies were used for an internal negative 
control (Table 4.1).  Cells were centrifuged (377 X g for 10 minutes), and primary 
antibodies were added in 1% BSA in PBS solution. Samples were placed on ice and 
incubated for 45 minutes; samples then were washed in ice-cold 1% BSA in PBS 
solution and centrifuged (377 X g for 10 minutes). The washing and centrifugation steps 
were repeated 3 times. Cells were stored at 4°C until flow cytometric analysis. The 
secondary FITC labeled antibody for CD90 was diluted in 1% BSA in PBS solution and 
incubated on ice for 30 minutes and then washed in ice-cold 1% BSA in PBS solution 
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and centrifuged (377 X g for 10 minutes). The washing and centrifugation steps were 
repeated 3 times. Cells were stored at 4°C until flow cytometric analysis (FACSAria 
flow cytometer, BD Biosciences, Mississauga, ON). 
Table 4.1 Characteristics and source of antibodies used for flow cytometric analysis of 
MSC surface markers and antibody isotypes used for internal negative controls.   
CD marker Fluorochrome Emission 
wave-
length  
(nm) 
Excitation 
wave-
length 
 (nm) 
Source 
CD34 Allophycocyanin 660 650 AbD Serotec, Raleigh, 
NC 
CD44 Phycoerythrin 667 496 Biolegend, San Diego, 
CA 
CD45 Allophycocyanin 660 650 AbD Serotec, Raleigh, 
NC 
CD90 NA NA NA Accurate Chemical & 
Scientific Corporation, 
Westbury, NY 
CD14 R Phycoerythrin-
cyanine 5.1 
693 565 Beckman Coulter 
Canada, LP, 
Mississauga, ON 
CD29 R Phycoerythrin-
cyanine 5.1 
693 565 Biolegend, San Diego, 
CA 
MHCII FITC 519 495 AbD Serotec, Raleigh, 
NC 
CD79 Alexa Fluor 647 665 650 AbD Serotec, Raleigh, 
NC 
IgG2a (mouse) R Phycoerythrin-
cyanine 5.1 
693 565 Beckman Coulter 
Canada, LP, 
Mississauga, ON 
IgG1k (mouse) Phycoerythrin 667 496 Biolegend, San Diego, 
CA 
IgG1 (mouse) Allophycocyanin 660 650 AbD Serotec, Raleigh, 
NC 
IgG2bk (rat) Phycoerythrin 667 496 Biolegend, San Diego, 
CA 
IgG2b Phycoerythrin 667 496 AbD Serotec, Raleigh, 
NC 
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IgG1 (mouse) Alexa Fluor 647 665 650 AbD Serotec, Raleigh, 
NC 
IgM (mouse) FITC 519 495 AbD Serotec, Raleigh, 
NC 
IgG1 (mouse) FITC 519 495 AbD Serotec, Raleigh, 
NC 
NA = Not applicable. 
4.3.7. Real time quantitative PCR (qPCR) 
Cultured and expanded cells from the second passage of each of the 5 fractions and the 
one unsorted group, from both bone marrow and muscle tissue, were seeded in 6-well 
plates at 200 cells/cm
2 
in triplicate. Half of the wells were induced with osteogenic 
medium, and the other half were maintained in standard medium to serve as control 
cultures. Growth of the paired cultures was stopped on day 7 and total RNA was 
extracted (Aurum total RNA mini kit, Bio-Rad Laboratories, Hercules, CA) from the 
cells. The cDNA was synthesized from total RNA via a cDNA synthesis kit (iScript 
cDNA synthesis kit, Bio-Rad Laboratories, Hercules, CA)  Primers derived from the 
coding regions of osteocalcin were as follows: forward, 5’-
CTGGGCCAGGACTCCGCATCT-3’; and reverse, 5’-
AGCCAGCTCGTCACAGTCTGGGTTG-3’. Primers derived from the coding regions 
of RUNX2 were as follows: forward, 5’-CAGACCAGCAGCACTCCATA-3’; and 
reverse, 5’-CAGCGTCAACACCATCATTC-3’. Primers derived from the coding 
regions of osterix were as follows: forward, 5’-GGCTATGCCAATGACTACCC-3’; and 
reverse, 5’-GGTGAGATGCCTGCATGGA-3’. Expression of the osteocalcin (OCN), 
RUNX2, and osterix genes were quantified via real-time PCR assay with a mix (iQ 
SYBR Green Supermix, Bio-Rad Laboratories, Hercules, CA)  The PCR assay was 
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performed on a thermal cycler (Rotorgene-6 RG 3000, Corbett Research, Montreal, QC). 
Cycling conditions were as follows: 95°C for 5 minutes; 35 cycles of 95°C for 15 
seconds, 56°C for 30 seconds for OCN (57.7
o
C for 30 seconds for RUNX2 and osterix), 
72°C for 45 seconds, and melting from 55° to 99°C. Nuclease-free water instead of 
cDNA was used as a negative control sample. The housekeeping gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) was used to normalize the expression of each gene 
of interest.(39, 40) 
4.3.7.1. qPCR statistical analysis  
 The data comprised gene expressions across 5 fractions and 1 unsorted control obtained 
from 2 tissues of 1 horse, with 3 replicate samples taken from each tissue. The study 
design had a split-plot character with samples within tissues representing whole-plots 
and fractions within each sample corresponding to sub-plots. Gene expression was 
quantified with real-time quantitative PCR.  The outcome was computed using the 
comparative CT method,(41, 42) or 2 to the power of the negative difference of 
housekeeping gene (GAPDH) and gene of interest (GOI) CT values to a baseline 
medium (SM). Outcomes for 3 genes (OCN, Runx, osterix) were analysed separately. 
The analysis used linear mixed models with random effects of samples (within tissues), 
after cubic root transformation of the outcome.  The linear mixed model assumptions 
were validated by residual analysis and found to be acceptable for all genes with this 
particular transformation. The linear mixed model included fixed effects of tissues and 
fractions as well as their interaction. Least squares means were back-transformed to the 
scale of the outcome as estimated medians with 95% confidence intervals.  The 
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statistical analysis was carried out using SAS (proc mixed) software (SAS, version 9.2, 
SAS Institute Inc, Cary, NC), and the significance level was set at P<0.05.  
4.4. Results 
4.4.1. Microscopic analysis of each fraction 
Both MMSCs and BMSCs had cells in each of the sorted fractions 1-5.  Cells 
from all cell sources and fractions adhered to polystyrene plastic.  The cell recovery 
from GrFFF sorting system was approximately 50%.  The highest number of cells was 
found in fractions 2, 3, and 4 from both tissues.  
4.4.2. Nodule quantification 
BMSC fractions 2, 4, and 5 had noticeably more von Kossa and alkaline 
phosphatase positive nodules present and BMSC fractions 1, 3, and the unsorted control 
BMSC population had fewer.  Each of the 5 MMSC fraction cultures had noticeably 
more von Kossa and alkaline phosphatase positive nodules present and the unsorted 
control MMSC population had fewer.  Figure 4.1 shows representative photomicrograph 
of von Kossa and alkaline phosphatase positive nodules. No substantial differences in 
average nodule area, perimeter, or stain intensity were noted between tissues or 
fractions.(Table 4.2) Average intensity is a measure of amount of light that reaches the 
camera. Therefore, higher intensities represent less stain uptake of nodules and lower 
intensities represent more stain uptake of nodules. 
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Figure 4.1 Representative photomicrograph of von Kossa and alkaline phosphatase 
positive histochemical staining for equine muscle derived  mesenchymal stem cells 
cultured from fraction 1.  Magnification 10X. Bar = 200 µm. 
 
 
 
 
 
 
 
 
 118 
 
Table 4.2 Raw data of nodule quantification. UC= Unsorted control cells. SD= Standard 
deviation. 
 
 
4.4.3. Real time quantitative PCR 
 Osteogenic capacity was determined on the basis of gene expression of OCN, 
RUNX2, and osterix measured in sorted fractions 1-5, as well as in unsorted control, 
from both tissues (muscle and bone marrow). MMSC fractions 1, 3, and 5 had 
significantly higher (P<0.05) RUNX2 expression after differentiation with osteogenic 
medium than did the control samples cultured in standard medium. There were no 
significant differences in OCN or osterix expression between differentiated and 
nondifferentiated cultures of MMSCs. The BMSC fraction 3 had significantly higher 
(P<0.05) OCN, RUNX2, and osterix expression after differentiation with osteogenic 
Tissue Fraction 
Number of 
nodules in 
20 fields  
Mean area 
(mm
2
) ±SD 
Mean 
intensity 
±SD 
Mean 
perimeter 
(mm) ±SD 
Muscle 1 23 0.1 ± 0.7 40 ± 9 1.2 ± 0.4 
Muscle 2 8 0.16 ± 0.1 37 ± 7 1.5 ± 0.6 
Muscle 3 4 0.07 ± 0.03 43 ± 4 1 ± 0.2 
Muscle 4 2 0.23 ± 0.004 38 ± 5 1.9 ± 0.02 
Muscle 5 12 0.03 ± 0.01 42 ± 5 0.6 ± 0.2 
Muscle UC 0 0 0 0 
Bone   Marrow 1 0 0 0 0 
Bone Marrow 2 18 0.06 ± 0.02 40 ± 6 1 ± 0.2 
Bone Marrow 3 0 0 0 0 
Bone Marrow 4 7 0.03 ± .03 42 ± 4 0.7 ± 0.3 
Bone Marrow 5 8 0.09 ± 0.03 31 ± 8 1.2 ± 0.3 
Bone Marrow UC 5 0.09 ± 0.05 26 ± 4 1.2 ± 0.3 
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medium than did the control samples cultured in standard medium.  BMSC fraction 5 
had significantly higher (P<0.05) OCN, and RUNX2 expression after differentiation 
with osteogenic medium than did the control samples cultured in standard medium.  
BMSC fraction 4 had highly significant (P≤0.00001) OCN, RUNX2 and osterix 
expression after differentiation with osteogenic medium in comparison with the control 
samples cultured in standard medium. The OCN expression was 20 fold that of cells in 
SM. The RUNX2 and Osterix expression was 57 fold that of cells in SM.  None of the 
unsorted control MMSCs or BMSCs showed significant differences in OCN, RUNX, or 
osterix expression between differentiated and nondifferentiated cultures of MMSCs.  
(Figure 4.2A-B) 
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Figure 4.2 Graphical representation of qPCR data.  Back-transformed estimates with 
95% confidence intervals from statistical model for real-time PCR assay of OCN, 
RUNX2, and osterix gene expression for 5 sorted fractions (F1-5) of MSCs and one 
unsorted control (UC) derived from muscle (A) and bone marrow (B).  Note the 
extremely high expression of all three osteogenic markers in bone marrow fraction 4 
when compared to other tissue and fractions.  Note the difference in x-axis scales 
between muscle and bone marrow graphs. * Significant (P≤0.05) expression of gene of 
interest compared to cultures in standard medium (horizontal black line). ‡Highly 
significant (P≤0.00001) expression of gene of interest compared to cultures in standard 
medium.   GapdH: GOI = Ratio of glyceraldehyde 3-phosphate dehydrogenase gene to 
the gene of interest. 
4.4.4. Flow cytometric analysis 
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Cells isolated from the second passage of each of the 5 fractions and the one 
unsorted control from both bone marrow and muscle tissue were cultured via standard 
conditions and each positively expressed CD90, CD44 and CD29 and lacked expression 
of CD45, CD34, CD14, CD79, and MHCII as determined on the basis of flow 
cytometric data.  Triple stained combinations were highly positive for CD29-CD44, 
CD29-CD90, and CD44-CD90 expression. Triple stained combinations were negative 
for CD14-CD79, CD14-MHCII, and CD79-MHCII expression.  Results were similar 
across tissues, fractions and unsorted controls.  The unstained flow cytometric analysis 
for assessment of the granularity and size of cells in the fraction subpopulations, and 
unsorted whole population, revealed a distinctly different population in bone marrow 
fraction 4 and muscle fraction 2 (Figure 4.3). 
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Figure 4.3 Results of  flow cytometric analysis of MSCs cultured from five sorted 
fractions (F1-5) and one unsorted control (UC) derived from equine muscle (M), bone 
marrow (BM) and unstained for assessment of the population granularity (x axis) and 
size (y axis). Dot plot and corresponding histogram graphical representation of the 
subpopulations depict a distinctly different population in bone marrow fraction 4 and 
muscle fraction 2. The fluorescence intensity (arbitrary units) is depicted. 
4.5. Discussion and Conclusions 
 This is the first study to compare the osteogenic capabilities of subpopulations of 
equine derived MMSCs and BMSCs sorted using non-equilibrium GrFFF or any other 
sorting system.  As expected, several subpopulations with varying degrees of osteogenic 
potential were present in each tissue.  The fractions of cells had different osteogenic 
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gene expression based on qPCR, and different cell size and granularity based on flow 
cytometry.  These subpopulations were previously found to have trilineage 
differentiation capabilities, thus have not been altered by the sorting process.(Chapter 3) 
Across all tissues, fractions and unsorted controls, all cells’ surface markers were 
consistent with what one would expect for MSCs.(29, 38)  Therefore, sorting systems 
that rely on the cell surface markers alone may have missed the subpopulation 
differences found in this study.  Evidence from this study indicates that cell sorting by 
properties other than cell surface markers is essential when the phenotype has not been 
completely elucidated.  
Interestingly, most of the fractionated BMSC and MMSC cultures had more von 
Kossa and alkaline phosphatase positive nodules present than the unsorted control 
BMSC and MMSC populations.  This revealed how very differently the same population 
of cells acts when separated into subpopulations.  In this case the subpopulations 
displayed more osteogenic activity than did the population as a whole.  We believe this 
finding is explained by the concept of a MSC microenvironment(43-46) that is a niche 
made up of other cells, soluble molecules, and other naïve MSCs.(46) When this niche is 
altered by sorting cell populations into subpopulations as was done in this study, it is 
reasonable to expect the subpopulations to behave differently from one another and from 
the original unsorted population.(46, 47) 
RUNX2 is upregulated alone in the MMSCs subpopulations.  Perhaps these cells 
are at an earlier stage of differentiation than the BMSCs and therefore only express 
RUNX2.  In comparison, particularly in fraction 4, all three genes are upregulated in the 
BMSCs. Perhaps these BMSCs are more mature and therefore have a more developed 
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gene expression profile.  Also the degree of upregulation of fraction 4 of the BMSCs is 
impressive with the OCN expression at 20 fold that of the SM control, and RUN2 and 
Osterix expression at 57 fold that of the SM control. Potentially this would be the ideal 
population to target in future studies. 
The lack of difference between fractions, tissues, and unsorted controls in nodule 
assays paired with the very significant differences in gene expression can potentially be 
attributed to the relative disparity in sensitivity between qPCR assays and nodule assays. 
As the nodule assay is not as sensitive as the qPCR assay, it is possible that more nodule 
data points would be required before revealing any significant differences. Also nodule 
quantification is done in 2 dimensions while the nodule itself it a 3 dimensional entity. 
There could be a loss of information due to the fact that the height of the nodule was not 
measured.  
The main limitation of this study was the use of only one horse.  Inter-horse 
variation can be significant and could affect the results.  The findings need to be 
evaluated in more horses in the future.  The main drawback of using this sorting system 
is the low number of cells that can be fractionated per run.(28) This study increased 
sorting throughput by pooling fractions collected at the same retention times from 
repeated runs as described in chapter 3.  An expansion step after the sorting process was 
also employed, and was a simple way of compensating for the low initial throughput.  
Others have set up two GrFFF channels in parallel to increase sorting throughput,(33) 
and placed a coating on the PVC in the GrFFF system that improved the sample 
returns.(48) 
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In equine regenerative medicine, identification of the source of MSCs with the 
optimum osteogenic capability has been the focus of much evaluation.(Chapter 2) (27, 
49-51)It is evident that the variation of MSCs within each source must also be taken into 
consideration.(Chapter 3) (25)Techniques for sorting and enrichment of MSCs appear 
vital to the isolation of the equine MSC phenotypes that are ideal for bone healing.   
In summary, subpopulations sorted from equine MMSCs and BMSCs with 
GrFFF differ in their osteogenic potential.  MMSCs may be more appropriate for 
stimulation of regeneration of other tissues types. Whereas, bone marrow derived MSCs 
from fraction 4 using the method described here, may have greater bone healing 
potential because they express high level of osteogenic gene markers.  Further 
clarification of MSC subpopulation phenotypes is necessary to determine the optimum 
ultrapure population for the intended application.  
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5. CONCLUSION 
5.1    Characterization and proliferation 
This study confirmed that cells derived from equine muscle and periosteal tissues 
can be characterized as MSCs as determined by morphology, adherence to polystyrene 
plastic (cell culture substrate), trilineage differentiation, and the detection of stem cell 
surface markers with immunofluorescence and flow cytometric analyses.  It was found 
that equine MMSCs and PMSCs have superior proliferative capacity to that of BMSCs. 
Analysis of data from the present study revealed that BMSCs proliferated more slowly 
than did MMSCs, PMSCs, and AMSCs. This is consistent with previous findings that 
muscle-derived cells yield greater cell culture numbers within a shorter time frame than 
do bone marrow–derived cells.(1, 2) In light of this, bone marrow may not be the 
optimum tissue for use in bone healing when time to culture clinically useful numbers of 
autogenous cells is considered. The slow proliferation of bone marrow–derived MSCs 
could have been attributable to the low number of proliferative cells in bone marrow 
aspirates. On the basis of a CFU fibroblast assay, the frequency of MSCs in the 
mononuclear cell fraction of equine marrow is reported to be 1 in 4.2 X 10
3
 cells and to 
differ among horses by 10-fold.(3)  The small fraction of proliferative cells among the 
total cell isolates may contribute to the 1 to 2 weeks of extra expansion time needed for 
bone marrow–derived MSCs over the expansion time required for other equine sources 
of MSCs.(4, 5) This points to the need for a method to isolate and concentrate this small 
proliferative fraction of cells before culture.  This has been addressed in one equine 
study using a bone marrow processing system designed for humans, and the results were 
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encouraging with a reported red blood cell reduction of 92±3%, and marrow 
mononuclear cell recovery of 91±15%.(6)  The limitations were the high cost of the 
system required to achieve this reduction, the large amount of bone marrow needed for 
the system to function, and the fact that the system was not fully optimized for equine 
samples.  This study left room for improvement in the cell-sorting method used for 
removal of contaminant cells that physically impede MSC adherence and thereby hasten 
the expansion process for bone marrow and other tissue sources.(7)  
5.2     Stem cell sorting systems 
To this end, this study validated the use of non-equilibrium GrFFF as a sorting 
method for equine derived BMSCs as well as MMSCs, PMSCs, and AMSCs.  The cells 
from each source were driven by gravity into different velocity regions, then fractions, 
based on differences in mass, size, and surface antigens.  Other sorting systems using 
counterflow centrifugal elutriation have been applied to human umbilical cord-derived 
stem cells to obtain homogenous subpopulations based on size, morphology, and 
proliferative activity.(8)  A method based on cell size has been validated with equine 
MSCs and confirmed the ability to isolate more rapidly proliferating MSC 
subpopulations from equine umbilical cord matrix.(9)  Currently fluorescence-activated 
cell sorting (FACS) is the standard for sorting populations and subpopulations of 
cells.(7)  However, cells are tagged by antibodies and fluorescent labels in preparation 
for FACS thus changing their cell surface characteristics and impeding post-FACS 
assays.(10) Therefore the GrFFF technology is superior because it is a tag-less system of 
stem cell sorting that will avoid augmentation of the MSCs.(7)  Perhaps most 
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importantly, GrFFF allows for the MSCs to be maintained under sterile conditions also 
allowing for further culture, expansion, assays, and use in cell based therapies after 
fractionation.(10)  In this study I confirmed that equine derived MMSCs, PMSCs, 
BMSCs, and AMSCs can be sorted by non-equilibrium GrFFF while maintaining 
viability for further assays. Future research could be aimed at comparing sorting 
techniques using equine MSCs but with the current state of the literature, the sorting 
techniques are difficult to compare because they sort based upon different parameters. 
5.3     Optimum source for osteogenic capactity 
 In equine regenerative medicine, identification of the source of MSCs with the 
optimum osteogenic capability has been the focus of much evaluation.(11-14)  It is 
unlikely that a single donor source of MSCs will be superior for regeneration of tissue 
from all different germ layers.(15)  This study showed MMSCs and PMSCs have 
osteogenic potential comparable to that of AMSCs and BMSCs, therefore broadening 
the MSC source options for clinicians. However, it is well known that MSCs derived 
from a single source are made up of a heterogeneous population and therefore evident 
that the variation of MSC phenotypes within each source must also be taken into 
consideration.(9)   
 Across all tissues, fractions and unsorted controls, all cells’ surface markers were 
consistent with what one would expect for equine MSCs based upon the current 
published works in the field.(16, 17) Although there are many CD markers that have 
been evaluated, the findings of the work described in this thesis and by others show 
equine MSCs cells are most consistently positive for CD 90, CD 44, and CD 29 and 
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negative for CD 34, CD 45.(16-18)  In the human MSCs field, the Mesenchymal and 
Tissue Stem Cell Committee of the International Society for Cellular Therapy have 
defined the minimal criteria for marker expression.(19)  In the equine MSCs field, 
definition of minimal criteria has not been reached due to lack of antibody cross 
reactivity, specific equine monoclonal antibodies, and therefore a lack of proper 
immunophenotyping.(17, 20)  No specific immunophenotype was elucidated in the 
findings of this thesis, however it was evident that the subpopulations were different in 
size and granularity based on flow cytometry of the unstained subpopulations. 
Interestingly, the subpopulations differed in osteogenic capability as well.  Gene 
expression of osteocalcin (OCN), Runx2, and osterix were quantified with qPCR 
revealing several fractions from both MMSCs and BMSCs to be significantly increased, 
some highly, from the baseline expression in standard media.  However, the nodule 
quantification findings did not reflect the outstanding difference that was noted in the 
gene expression profiles.  Perhaps this can be attributed to the fact that the nodule 
quantification assay is far less sensitive than qPCR and might therefore have only shown 
significance with a higher n. The subpopulation differences established in this study are 
important findings that sorting systems relying on the cell surface markers alone may 
have missed.  One group attempted flow cytometric characterization of equine AMSCs 
in order to elucidate the phenotype of these MSCs, only to conclude that “further 
insights are necessary to optimize cell phenotype definition, to identify specific 
subpopulations and to make results among laboratories completely reproducible.”(21) 
Another group demonstrated convincingly that several cell surface molecule changes 
took place during the first few weeks of  establishment of MSC populations, which may 
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account for the elusiveness of a phenotype amongst researchers.(22) Evidence from the 
work presented in this thesis indicates that when the exact phenotype of interest is 
unknown, cell sorting by cell surface markers could be combined with sorting by other 
properties, as done with GrFFF, to attempt elucidation of that phenotype. 
5.4     Microenvironment or niche 
 It is expected that a fraction of a population should have similar properties to the 
whole population.  However interestingly, most of the fractionated BMSC and MMSC 
cultures had von Kossa and alkaline phosphatase positive nodules present and the 
unsorted control BMSC and MMSC populations had fewer nodules present.  Also, 
BMSC fraction 4 had highly significant (P≤0.00001) OCN, RUNX2 and osterix 
expression after differentiation with osteogenic medium in comparison with the control 
samples cultured in standard medium while none of the unsorted control MMSCs or 
BMSCs showed significant differences in OCN, RUNX, or osterix expression.  These 
findings revealed how very differently the same population of cells acts when separated 
into subpopulations.  In this case the subpopulations displayed more osteogenic activity 
than did the population as a whole.  This finding is consistent with another group who 
found that some fractions of non-equilibrium GrFFF sorted human adipose derived 
MSCs had more adipogenic activity than the unsorted control MSCs.(23)  I hypothesize 
that this finding may be explained by the concept of a MSC microenvironment(24-27) 
that is a niche made up of other cells, soluble molecules, and other naïve MSCs.(27, 28)  
When this niche is altered by sorting cell populations into subpopulations, as was done 
in this study, it is reasonable to expect the subpopulations to behave differently from one 
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another and from the original unsorted population.  Obviously there may be great value 
in this in vitro finding, but interpretation must be done with care as the in vitro 
environment is not always representative of the in vivo environment that is in fact the 
long term milieu for these cultured cells.(29)  
5.5     Limitations 
One of the limitations of the present study was the use of a single osteoblastic 
marker in the characterization phase of the experiments. Evaluation of the expression of 
additional genes as osteoblastic markers may have highlighted differences in osteogenic 
potential among tissues, considering that no significant differences were detected with 
use of one marker.  However, as the primary focus of this study was to confirm 
osteogenic differentiation as part of trilineage differentiation, osteocalcin was used as 
the sole marker.(30, 31)  Finally, although there was no significant difference (P = 0.17) 
in osteocalcin expression among the 4 unsorted tissues of the 10 horses, unsorted 
MMSCs showed the highest osteocalcin expression, and it is possible that an increased 
number of horses may yield data in which the differences were significant.  Subsequent 
experiments added two other markers and the varied findings were indication of the 
importance of using more than one marker.  The main limitation to the sorting phase of 
the experiments was the low cell throughput of the GrFFF sorting system.  To 
compensate for the low throughput, we pooled fractions collected at the same retention 
times from repeated runs, and added an expansion step after the sorting process.  We 
found these techniques resolved the issue easily. Finally, the use of only one horse in the 
last phase of the project assigns a low power to the analysis due to the possibility of 
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inter-horse variation, but does provide some preliminary evidence validating this 
approach.   
5.6     Future goals  
While the MMSCs were shown to have an ideal proliferative capacity, fraction 4 
of the BMSCs have a very desirable gene expression profile.  This begs the question as 
to whether future emphasis should be placed on upscaling production of this pro-
osteogenic subpopulation. Also, it is necessary to use more horses to repeat the portion 
of the experiment using non-equilibrium GrFFF for MSC purification and fractionation 
into subpopulations for further analysis of CD markers using flow cytometry.  More 
markers should be employed using a DNA microarray in efforts to elucidate the 
phenotype of the optimum subpopulation. With this information the GrFFF system 
would be employed to isolate the subpopulation of interest allowing for culture and 
expansion of an ultrapure population.  An in vivo osteogenic assessment would be called 
for first in a rodent model and then in a large animal model.  Potentially our results 
would be helpful for future research to use in sample size calculation to determine how 
many more horses the study should be repeated in to reach an appropriate power, 
evaluate inter-horse variation, and standardize a protocol for use of the non-equilibrium 
GrFFF system clinically.   
5.7     Summary 
To our knowledge, the study reported here is the first to confirm osteocalcin 
expression in equine muscle- and periosteum-derived MSCs, which indicates their 
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osteogenic potential.  While the characterization of muscle- and periosteum-derived 
MSCs broadens the choices available to clinicians who use MSCs in cell-based 
treatments, the heterogenous nature of MSC populations must remain a central focus in 
investigations of this nature. As shown here, subpopulations sorted from equine MMSCs 
and BMSCs with GrFFF, differ when it comes to osteogenic potential.  Therefore, 
techniques for sorting MSCs appear vital to isolate, and phenotype, the optimum 
homogeneous subpopulation that is ideal for equine bone healing. The ability to 
affordably and effectively sort equine MSCs with non-equilibrium GrFFF, as shown in 
this study, is promising for its future application in cell-based treatment of bone 
fractures in horses.  
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